View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2019	Mar. 12, 2020	Jun. 28, 2019
Document And Entity Information
Entity Registrant Name	HARROW HEALTH, INC.
Entity Central Index Key	0001360214
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 205,000,000
Entity Common Stock, Shares Outstanding		25,526,931
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents, including restricted cash of $200	$ 4,949	$ 6,838
Investment in Eton Pharmaceuticals	25,200	21,420
Accounts receivable, net	2,009	1,914
Inventories	3,301	1,834
Prepaid expenses and other current assets	1,308	837
Total current assets	36,767	32,843
Property, plant and equipment, net	5,375	6,375
Operating lease right-of-use assets	6,559
Intangible assets, net	2,337	3,059
Goodwill	332	2,227
TOTAL ASSETS	59,085	49,451
Current liabilities
Accounts payable and accrued expenses	7,702	6,250
Accrued payroll and related liabilities	2,117	2,283
Deferred revenue and customer deposits	57	119
Current portion of note payable, net of unamortized debt discount	1,772	2,529
Current portion of operating lease obligations	629
Current portion of finance lease obligations, net of unamortized discount	7	720
Total current liabilities	12,284	11,901
Operating lease obligations, net of current portion	6,338
Finance lease obligations, net of current portion and unamortized discount	26
Accrued expenses, net of current portion	800	800
Note payable, net of current portion and unamortized debt discount	12,219	11,999
TOTAL LIABILITIES	31,667	24,700
Commitments and contingencies
STOCKHOLDERS' EQUITY
Common stock, $0.001 par value, 50,000,000 shares authorized, 25,526,931 and 24,339,610 shares issued and outstanding at December 31, 2019 and 2018, respectively	26	24
Additional paid-in capital	101,728	98,938
Accumulated deficit	(74,043)	(74,211)
TOTAL HARROW HEALTH, INC STOCKHOLDERS' EQUITY	27,711	24,751
Noncontrolling interests	(293)
TOTAL EQUITY	27,418	24,751
TOTAL LIABILITIES AND EQUITY	59,085	49,451
Surface Pharmaceuticals [Member]
Current assets
Investment	3,747	4,947
Melt Pharmaceuticals [Member]
Current assets
Investment	$ 3,968

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Restricted cash	$ 200	$ 200
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	25,526,931	24,339,610
Common stock, shares outstanding	25,526,931	24,339,610

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues:
Total revenues	$ 51,165	$ 41,372
Cost of sales	(16,749)	(16,521)
Gross profit	34,416	24,851
Operating expenses:
Selling, general and administrative	33,096	29,243
Research and development	2,083	825
Impairment of long-lived assets	4,040
Total operating expenses	39,219	30,068
Loss from operations	(4,803)	(5,217)
Other income (expense):
Interest expense, net	(2,500)	(2,728)
Loss on sale of assets		(393)
Other income, net	630	103
Total other income, net	4,678	19,842
Income (loss) before income taxes	(125)	14,625
Income tax benefit, net
Total net income (loss) including noncontrolling interests	(125)	14,625
Net loss attributable to noncontrolling interests	293
Net income attributable to Harrow Health, Inc.	$ 168	$ 14,625
Basic net income per share of common stock	$ 0.01	$ 0.67
Diluted net income per share of common stock	$ 0.01	$ 0.61
Weighted average number of shares of common stock Outstanding, basic	25,323,159	21,917,570
Weighted average number of shares of common stock Outstanding, diluted	26,466,098	23,812,045
Melt Pharmaceuticals [Member]
Other income (expense):
Investment (loss) gain, net	$ 3,968
Surface Pharmaceuticals [Member]
Other income (expense):
Investment (loss) gain, net	(1,200)	4,947
Eton Pharmaceuticals [Member]
Other income (expense):
Investment (loss) gain, net	3,780	17,913
Product Sales, Net [Member]
Revenues:
Total revenues	51,137	41,334
License Revenues [Member]
Revenues:
Total revenues	$ 28	$ 38

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total Harrow Health, Inc. Stockholders' Equity [Member]	Total Noncontrolling Interests [Member]	Total
Balance at Dec. 31, 2017	$ 21	$ 91,430	$ (88,836)	$ 2,615		$ 2,615
Balance, shares at Dec. 31, 2017	20,623,129
Issuance of common stock in connection with: Exercise of warrants	$ 3	4,230		4,233		4,233
Issuance of common stock in connection with: Exercise of warrants, shares	3,275,162
Issuance of common stock in connection with: Vesting of RSUs, net of tax withholding
Issuance of common stock in connection with: Vesting of RSUs, net of tax withholding, shares	60,000
Issuance of common stock in connection with: Sale of stock, net of costs (ATM)		642		642		642
Issuance of common stock in connection with: Sale of stock, net of costs (ATM), shares	305,619
Issuance of common stock in connection with: Stock-based payment for services provided		150		150		150
Issuance of common stock in connection with: Stock-based payment for services provided, shares	75,700
Stock-based compensation expense		2,486		2,486		2,486
Net income (loss)			14,625	14,625		14,625
Balance at Dec. 31, 2018	$ 24	98,938	(74,211)	24,751		24,751
Balance, shares at Dec. 31, 2018	24,339,610
Issuance of common stock in connection with: Exercise of warrants	$ 2	811		813		813
Issuance of common stock in connection with: Exercise of warrants, shares	1,142,528
Issuance of common stock in connection with: Stock-based payment for services provided		234		234		234
Issuance of common stock in connection with: Stock-based payment for services provided, shares	15,000
Issuance of common stock in connection with: Exercise of employee stock options, net of tax withholding		(44)		(44)		(44)
Issuance of common stock in connection with: Exercise of employee stock options, net of tax withholding	29,793
Stock-based compensation expense		1,789		1,789		1,789
Net income (loss)			168	168	(293)	(125)
Balance at Dec. 31, 2019	$ 26	$ 101,728	$ (74,043)	$ 27,711	$ (293)	$ 27,418
Balance, shares at Dec. 31, 2019	25,526,931

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income (includes non-controlling interests)	$ (125)	$ 14,625
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization of property, plant and equipment	1,936	1,608
Amortization of intangible assets	209	235
Amortization of operating lease right-of-use assets	518
Amortization of debt issuance costs and discount	512	613
Loss on sale, impairments and disposal of assets	4,148	393
Stock based payment for services provided	234	150
Stock-based compensation	1,789	2,486
Changes in assets and liabilities, net of impairments and disposals:
Accounts receivable	(95)	(384)
Inventories	(2,271)	415
Prepaid expenses and other current assets	(471)	(123)
Accounts payable and accrued expenses	1,342	2,365
Accrued payroll and related liabilities	(166)	1,074
Deferred revenue and customer deposits	(62)	90
NET CASH PROVIDED BY OPERATING ACTIVITIES	950	687
CASH FLOWS FROM INVESTING ACTIVITIES
Repayment of note receivable		4
Proceeds on sale and disposal of assets	4
Investment in patent and trademark assets	(369)	(435)
Purchases of property, plant and equipment	(1,468)	(1,768)
NET CASH USED IN INVESTING ACTIVITIES	(1,833)	(2,199)
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on finance lease obligations	(743)	(691)
Payments on Park deferred acquisition obligation		(53)
Principal payments on note payable	(750)
Payments of costs related to amendment of note payable	(282)
Net proceeds from ATM sales of common stock		642
Net proceeds from exercise of warrants and stock options, net of taxes remitted for RSU's and options	769	4,233
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(1,006)	4,131
NET (DECREASE) INCREASE IN, CASH EQUIVALENTS AND RESTRICTED CASH	(1,889)	2,619
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year	6,838	4,219
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of year	4,949	6,838
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH
Cash and cash equivalents	4,749	6,638
Restricted cash	200	200
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD	4,949	6,838
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes	17	4
Cash paid for interest	1,967	2,097
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Purchase of property and equipment included in accounts payable	39
Right-of-use asset obtained in exchange for lease obligation	753
Eton Pharmaceuticals [Member]
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Investment (gain)/loss	(3,780)	(17,913)
Surface Pharmaceuticals [Member]
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Investment (gain)/loss	1,200	(4,947)
Melt Pharmaceuticals [Member]
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Investment (gain)/loss	$ (3,968)

Organization

12 Months Ended

Dec. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

NOTE 1. ORGANIZATION

Harrow Health, Inc. (together with its subsidiaries, partially owned companies and royalty arrangements unless the context indicates or otherwise requires, the “Company” or “Harrow”) specializes in the development, production and sale of innovative medications that offer unique competitive advantages and serve unmet needs in the marketplace through its subsidiaries and deconsolidated companies. The Company owns one of the nation’s leading ophthalmology pharmaceutical businesses, ImprimisRx. In addition to wholly owning ImprimisRx, the Company also has equity positions in Eton Pharmaceuticals, Inc. (“Eton”), Surface Pharmaceuticals, Inc. (“Surface”), and Melt Pharmaceuticals, Inc. (“Melt”), all companies that began as subsidiaries of Harrow. More recently, the Company founded drug development subsidiaries Mayfield Pharmaceuticals, Inc. (“Mayfield”), Radley Pharmaceuticals, Inc. (“Radley”), and Stowe Pharmaceuticals, Inc. (“Stowe”). Harrow also owns royalty rights in various drug candidates being developed by Surface, Melt, Radley and Mayfield. The Company intends to continue to create, and hold equity and royalty rights in, new businesses that commercialize drug candidates that are internally developed or otherwise acquired or licensed from third parties.

In December 2018, the Company amended its restated certificate of incorporation to change its corporate name from “Imprimis Pharmaceuticals, Inc.” to “Harrow Health, Inc.”.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Harrow has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, as well as Mayfield and Stowe, 70% majority controlled subsidiaries of Harrow as of December 31, 2019. The remaining 30% of Mayfield is owned by Elle Pharmaceutical, LLC (“Elle”), TGV-Health, LLC and its affiliated entities (collectively “TGV”) or other consultants. Mayfield was organized to develop women’s health-focused drug candidates. The remaining 30% of Stowe is owned by TGV. Stowe was organized to develop ophthalmic drug candidates. All inter-company accounts and transactions have been eliminated in consolidation.

Harrow consolidates entities in which we have a controlling financial interest. We consolidate subsidiaries in which we hold and/or control, directly or indirectly, more than 50% of the voting rights. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among others, allowance for doubtful accounts and contractual adjustments, renewal periods and discount rates for leases, realizability of inventories, valuation of investments in equity securities, deferred taxes, goodwill and intangible assets, recoverability of long-lived assets and goodwill, valuation of contingent acquisition obligations and deferred acquisition obligations, valuation of notes payable, and valuation of stock-based transactions with employees and non-employees. Actual results could differ from those estimates.

Liquidity

While there is no assurance, the Company believes cash generated from its operations, along with its existing cash resources, restricted cash and marketable securities of approximately $30,149 at December 31, 2019, will be sufficient to sustain the Company’s planned level of operations for at least the next twelve months. However, estimates of operating expenses and working capital requirements could be incorrect, and the Company could use its cash resources faster than anticipated. Further, some or all of the ongoing or planned activities may not be successful and could result in further losses.

The Company may seek to increase liquidity and capital resources by one or more of the following which may include, but are not limited to: the sale of assets and/or businesses, obtaining financing through the issuance of equity, debt, or convertible securities; and working to increase revenue growth through sales. There is no guarantee that the Company will be able to obtain capital when needed on terms it deems as acceptable, or at all.

Segments

The Company’s chief operating decision-maker is its Chief Executive Officer who makes resource allocation decisions and assesses performance based on financial information presented on as operating segments. The Company has identified two operating segments as reportable segments. See Note 18 for more information regarding the Company’s reportable segments.

Noncontrolling Interests

The Company recognizes any noncontrolling interest as a separate line item in equity in the consolidated financial statements. A noncontrolling interest represents the portion of equity ownership in a less-than-wholly owned subsidiary not attributable to the Company. Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors, such as decision-making rights, that are considered as well. The Company includes the amount of net income (loss) attributable to noncontrolling interests in consolidated net income (loss) on the face of the consolidated statements of operations.

The Company provides in the consolidated statements of stockholders’ equity a reconciliation at the beginning and the end of the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling interest that separately discloses:

	(1)	net income or loss;
	(2)	transactions with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and
	(3)	each component of other income or loss.

Revenue Recognition and Deferred Revenue

The Company recognizes revenue at the time of transfer of promised goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services (see Note 3).

Cost of Sales

Cost of sales includes direct and indirect costs to manufacture formulations and other products sold, including active pharmaceutical ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs and the write-off of obsolete inventory.

Research and Development

The Company expenses all costs related to research and development as they are incurred. Research and development expenses consist of expenses incurred in performing research and development activities, including salaries and benefits, other overhead expenses, and costs related to clinical trials, contract services and outsourced contracts.

Debt Issuance Costs and Debt Discount

Debt issuance costs and the debt discount are recorded net of notes payable and finance lease obligations in the consolidated balance sheets. Amortization expense of debt issuance costs and the debt discount is calculated using the effective interest method over the term of the debt and is recorded in interest expense in the accompanying consolidated statements of operations.

Intellectual Property

The costs of acquiring intellectual property rights to be used in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where we have identified an alternative future use for the acquired rights. Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks become more certain (see “—Goodwill and Intangible Assets” below). The Company began capitalizing certain costs associated with acquiring intellectual property rights during 2015; if costs are not capitalized they are expensed as incurred.

Income Taxes

As part of the process of preparing the Company’s consolidated financial statements, the Company must estimate the actual current tax liabilities and assess permanent and temporary differences that result from differing treatment of items for tax and accounting purposes. The temporary differences result in deferred tax assets and liabilities, which are included within the consolidated balance sheets. The Company must assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not more likely than not, a valuation allowance must be established which reduces the amount of deferred tax assets recorded on the consolidated balance sheets. To the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period, the impact will be included in income tax expense in the consolidated statement of operations.

The Company accounts for income taxes under the provisions of Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) 740, Income Taxes. As of December 31, 2019 and 2018, there were no unrecognized tax benefits included in the consolidated balance sheets that would, if recognized, affect the effective tax rate. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties in its consolidated balance sheets at December 31, 2019 and 2018, and has not recognized interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2019 and 2018. The Company is subject to taxation in the United States, California, Florida, Georgia, Illinois, New Jersey, New York, Tennessee, and Wisconsin. The Company’s tax years since 2000 may be subject to examination by the federal and state tax authorities due to the carryforward of unutilized net operating losses.

Cash and Cash Equivalents

Cash equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition.

Concentrations of Credit Risk

The Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance Corporation (“FDIC”) provides basic deposit coverage with limits up to $250 per owner. From time to time the Company has cash deposits in excess of FDIC limits.

Investment in Eton Pharmaceuticals, Inc.

In April 2017, the Company formed Eton as a wholly owned subsidiary. In June 2017 the Company lost voting and ownership control of Eton and it ceased consolidating Eton’s financial statements. At the time of deconsolidation, the Company recorded a gain of $5,725 and adjusted the carrying value in Eton to reflect the increased valuation of Eton and the Company’s new ownership percent in accordance with ASC 810-10-40-4(c), Consolidation. At the time of deconsolidation, the Company used the equity method of accounting as management determined that the Company had the ability to exercise significant influence over the operating and financial decisions of Eton. Under this method, the Company recognized earnings and losses of Eton in its consolidated financial statements and adjusted the carrying amount of its investment in Eton accordingly. During the years ended December 31, 2019 and 2018, the Company recorded equity in net loss of Eton of $0 and $3,507, respectively.

In November 2018, Eton closed on an initial public offering of 4,140,000 shares of its common stock at $6.00 per share for gross proceeds of approximately $24,800 (the “Eton IPO”). Following the close of the Eton IPO, the Company estimated its common stock position in Eton equaled 19.98% of the equity and voting interests issued and outstanding of Eton, and it ceased using the equity method of accounting for its investment in Eton. The Company recognizes earnings and losses of Eton in its consolidated financial statements based on the fair market value of the shares owned and adjust the carrying amount of the Company’s investment in Eton accordingly. Eton’s common stock currently trades on the NASDAQ Global Market exchange. At December 31, 2019, the fair market value of Eton’s common stock was $7.20 per share, the closing share price of Eton common stock on that day. In accordance with Accounting Standards Update (“ASU”) 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, for the year ended December 31, 2019, the Company recorded an investment gain from its Eton common stock position of $3,780 related to the change in fair market value of the Company’s investment in Eton during the measurement period. For the year ended December 31, 2018, the Company recorded an investment gain from its Eton common stock position of $21,420 related to the change in fair market value of the Company’s investment in Eton during the measurement period. As of December 31, 2019, the fair market value of the Company’s investment in Eton was $25,200.

Eton and the Company signed licensing agreements for two products developed by the Company whereby the Company assigned the product rights to Eton. Eton would pay the Company a $50 milestone payment upon patent issuance for each product and a royalty fee at a rate of six percent on the net sales of those two products. On December 26, 2017, one of the products had its patent issued and a $50 milestone fee was received by the Company in January 2018. In July 2018, Eton and the Company agreed to cancel the licensing agreement for one of the products and retain the product rights at the Company, in exchange of the Company paying Eton $50.

On May 6, 2019, the Company entered into an Asset Purchase Agreement (the “CT-100 Asset Purchase Agreement”) with Eton. Pursuant to the CT-100 Asset Purchase Agreement, Eton sold all of its right, title and interest in CT-100 back to the Company. Pursuant to the CT-100 Asset Purchase Agreement, the Company will make certain payments to Eton upon the achievement of certain development and commercial milestones. In addition, the Company is required to pay Eton a royalty in the low-single digit percentage range worldwide on a country-by-country basis on net sales for a period of the longer of 15 years from the date of the first commercial sale of a product subject to certain conditions.

Mark L. Baum, the Company’s Chief Executive Officer is a member of the Eton board of directors.

Accounts Receivable

Accounts receivable are stated net of allowances for doubtful accounts and contractual adjustments. The accounts receivable balance primarily includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental agencies), but for which payment has not been received. Charges to bad debt are based on both historical write-offs and specifically identified receivables. Accounts receivable are presented net of allowances for doubtful accounts and contractual adjustments in the amount of $76 and $270 as of December 31, 2019 and 2018, respectively.

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective markets compared with historical cost. Write-downs of inventories are considered to be permanent reductions in the cost basis of inventories.

The Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical ingredients on hand. The Company establishes reserves for excess and obsolete inventories as required based on its analyses.

Investment in Melt Pharmaceuticals, Inc.

In April 2018, the Company formed Melt as a wholly owned subsidiary. In January and March of 2019, Melt entered into definitive stock purchase agreements (collectively, the “Melt Series A Preferred Stock Agreement”) with certain investors and closed on the purchase and sale of Melt’s Series A Preferred Stock (the “Melt Series A Stock”), totaling approximately $11,400 of proceeds (collectively the “Melt Series A Round”) at a purchase price of $5.00 per share. As a result, the Company lost voting and ownership control of Melt and ceased consolidating Melt’s financial statements. In connection with the Melt Series A Preferred Stock Agreement, Melt also entered into a Registration Rights Agreement and agreed to use commercially reasonable efforts to file, or confidentially submit, a registration statement on Form S-1 with the United States Securities and Exchange Commission by September 30, 2020 relating to an initial public offering of its common stock.

At the time of deconsolidation, the Company recorded a gain of $5,810 and adjusted the carrying value in Melt to reflect the increased valuation of Melt and the Company’s new ownership interest in accordance with ASC 810-10-40-4(c), Consolidation.

The Company owns 3,500,000 common shares (which is approximately 44% of the equity interest as of December 31, 2019) of Melt and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Melt. Under this method, the Company recognizes earnings and losses of Melt in its consolidated financial statements and adjusts the carrying amount of its investment in Melt accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Melt. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2019, the Company recorded equity in net loss of Melt of $1,842. As of December 31, 2019, the carrying value of the Company’s investment in Melt was $3,968.

See Note 4 for more information and related party disclosure regarding Melt.

Investment in Surface Pharmaceuticals, Inc.

In April 2017, the Company formed Surface as a wholly owned subsidiary. In May and July 2018, Surface entered into and closed on definitive stock purchase agreements with an institutional investor for the purchase of Surface’s Series A Preferred Stock (the “Surface Series A Stock”) that resulted in total proceeds to Surface of approximately $21,000. At the time of the first closing in May 2018, the Company lost voting and ownership control of Surface and it ceased consolidating Surface’s financial statements. The Surface Series A Stock (i) was issued at a purchase price of $3.30 per share; (ii) will vote together with the common stock and all other shares of stock of Surface having general voting power; (iii) will be entitled to the number of votes equal to the number of shares of preferred stock held; (iv) will hold liquidation preference over all other equity interests in Surface; and (v) will have mandatory conversion requirements into Surface common stock upon events including an underwritten initial public offering of Surface common stock or similar transaction.

At the time of deconsolidation, the Company recorded a gain of $5,320 and adjusted the carrying value in Surface to reflect the increased valuation of Surface and the Company’s new ownership percent in accordance with ASC 810-10-40-4(c).

The Company owns 3,500,000 common shares (which is approximately 30% of the equity interest as of December 31, 2019, and calculated after the second closing of the sale Series A Preferred Stock in July 2018) of Surface and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Surface. Under this method, the Company recognizes earnings and losses of Surface in its consolidated financial statements and adjusts the carrying amount of its investment in Surface accordingly. The Company’s share of earnings and losses are based on the shares of common stock and in-substance common stock of Surface held by the Company. Any intra-entity profits and losses are eliminated. During the years ended December 31, 2019 and 2018, the Company recorded equity in net loss of Surface of $1,200 and $373, respectively. As of December 31, 2019, the carrying value of the Company’s investment in Surface was $3,747.

See Note 5 for more information and related party disclosure regarding Surface.

Property, Plant and Equipment

Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful life of the asset. Leasehold improvements and capital lease equipment are amortized over the estimated useful life or remaining lease term, whichever is shorter. Computer software and hardware and furniture and equipment are depreciated over three to five years.

Business Combinations

The Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially with respect to intangible assets, estimated contingent consideration payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible assets the Company has acquired or may acquire in the future include but are not limited to:

	●	future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and

	●	discount rates utilized in valuation estimates.

Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate.

Goodwill and Intangible Assets

Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks become more certain. At that time, the Company capitalizes third-party legal costs and filing fees associated with obtaining and prosecuting claims related to its patents and trademarks. Once the patents have been issued, the Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life, generally 20 years, using the straight-line method. Trademarks are an indefinite life intangible asset and are assessed for impairment based on future projected cash flows as further described below.

The Company reviews its goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event or a change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes in circumstances considered as impairment indicators include but are not limited to the following:

	●	significant underperformance of the Company’s business relative to expected operating results;

	●	significant adverse economic and industry trends;

	●	significant decline in the Company’s market capitalization for an extended period of time relative to net book value; and

	●	expectations that a reporting unit will be sold or otherwise disposed.

The goodwill impairment test consists of a two-step process as follows:

Step 1. The Company compares the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair value of each reporting unit is determined using a discounted cash flow valuation analysis. The carrying amount of each reporting unit is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount, relative revenues or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its fair value, an indication exists that the reporting unit’s goodwill may be impaired and the Company then performs the second step of the impairment test. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required.

Step 2. If further analysis is required, the Company compares the implied fair value of the reporting unit’s goodwill, determined by allocating the reporting unit’s fair value to all of its assets and its liabilities in a manner similar to a purchase price allocation, to its carrying amount. If the carrying amount of the reporting unit’s goodwill exceeds its fair value, an impairment loss will be recognized in an amount equal to the excess.

Impairment of Long-Lived Assets

Long-lived assets, such as property, plant and equipment, purchased intangibles subject to amortization and patents and trademarks, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated balance sheet, if material (See Note 9).

Park Restructuring

In August 2019, the Company’s subsidiary, Park Compounding, Inc. (“Park”), and Noice Rx, LLC (“Noice”) terminated an Asset Purchase Agreement dated July 26, 2019 (the “Park Purchase Agreement”), between the parties. Under the terms of the Park Purchase Agreement, Park had agreed to sell substantially all its assets associated with its non-ophthalmology pharmaceutical compounding business to Noice, including its pharmacy facility and equipment located in Irvine, California. The closing of the sale transaction was dependent on the California State Board of Pharmacy approving of the sale and issuing a temporary pharmacy and sterile license permit to Noice, which did not occur and led to Park ceasing operations at the close of business on August 27, 2019. As a result, the Company restructured its Park business, ceased operations at its Irvine, California-based pharmacy, and facilitated the transition of certain compounded formulations and related equipment from Park to the Company’s New Jersey-based compounded pharmaceutical production facilities (the “Park Restructuring”). As a result of the Park Restructuring, the Company incurred non-cash impairment costs of approximately $3,781 related to assets held at Park, primarily associated with property, plant, equipment, inventory, goodwill and other intangible assets, and $480 in one-time costs related to severance packages and other costs associated with the Park Restructuring during the year ended December 31, 2019.

The Company has reduced the Park compounded product formulary to seven base formulations, based on factors including unit order volumes, revenues and gross margin percentages, and ImprimisRx expects to have re-acquired approximately half of Park’s historical revenues during the first quarter of 2020.

Fair Value Measurements

Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels:

●	Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.
●	Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
●	Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.

At December 31, 2019 and 2018, the Company measured its investment in Eton on a recurring basis. The Company’s investment in Eton is classified as Level 1 as the fair value is determined using quoted market prices in active markets for the same securities. As of December 31, 2019, the fair market value of the Company’s investment in Eton was $25,200.

The Company’s financial instruments included cash and cash equivalents, investment in Eton, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred revenue and customer deposits, notes payable and operating and finance leases. The carrying amount of these financial instruments, except for notes payable and finance leases, approximates fair value due to the short-term maturities of these instruments. The Company’s restricted short-term investments are carried at amortized cost, which approximates fair value. Based on borrowing rates currently available to the Company, the carrying values of the notes payable and operating and finance leases approximate their respective fair values.

Stock-Based Compensation

All stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units (“RSUs”) and restricted stock, are recognized in the consolidated financial statements based upon their estimated fair values. The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo Simulation to estimate the fair value of stock-based awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates.

Basic and Diluted Net Income per Common Share

Basic net income per common share is computed by dividing income attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted income per share is computed by dividing the income attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options and warrants, outstanding during the period.

Basic and diluted net income per share is computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using the treasury stock or “if converted” method) from stock options, unvested restricted stock units (“RSUs”) and warrants were 4,848,459 and 6,201,355 at December 31, 2019 and 2018, respectively, and are excluded in the calculation of diluted net income per share for the periods presented, because the effect is anti-dilutive for that time period. Included in the basic and diluted net income per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying vested RSUs at December 31, 2019 and 2018 was 324,303 and 236,693, respectively.

The following table shows the computation of basic net income per share of common stock for the years ended December 31, 2019 and 2018:

	For the		For the
	Year Ended		Year Ended
	December 31, 2019		December 31, 2018

Numerator – net income	$	168	$	14,625
Denominator – weighted average number of shares outstanding, basic		25,323,159		21,917,570
Net income per share, basic	$	0.01	$	0.67

For the years end December 31, 2019 and 2018, the Company computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during that period. Diluted common equivalent shares for the years ended December 31, 2019 and 2018, respectively,consisted of the following:

	For the Year Ended		For the Year Ended
	December 31, 2019		December 31, 2018
	Shares		Shares
Diluted shares related to:		25,323,159		21,917,570
Warrants		488,498		1,844,272
Stock options		654,441		50,203
Dilutive common equivalent shares		26,466,098		23,812,045

The following table shows the computation of diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding for the years ended December 31, 2019 and 2018:

	For the		For the
	Year Ended		Year Ended
	December 31, 2019		December 31, 2018

Numerator – net income	$	168	$	14,625
Weighted average number of shares outstanding, basic		25,323,159		21,917,570
Dilutive common equivalents		1,142,939		1,894,475
Denominator – number of shares used for diluted earnings per share computation		26,466,098		23,812,045
Net income per share, diluted	$	0.01	$	0.61

Recently Adopted Accounting Pronouncements

In February 2016, the FASB issued new lease accounting guidance in ASU 2016-02, Leases (Topic 842). This new guidance was initiated as a joint project with the International Accounting Standards Board to simplify lease accounting and improve the quality of and comparability of financial information for users. This new guidance would eliminate the concept of off-balance sheet treatment for “operating leases” for lessees for the vast majority of lease contracts. Under ASU 2016-02, at inception, a lessee must classify all leases with a term of over one year as either finance or operating, with both classifications resulting in the recognition of a defined “right-of-use” asset and a lease liability on the balance sheet. However, recognition in the income statement will differ depending on the lease classification, with finance leases recognizing the amortization of the right-of-use asset separate from the interest on the lease liability and operating leases recognizing a single total lease expense. Lessor accounting under ASU 2016-02 is substantially unchanged from the previous lease requirements under GAAP. ASU 2016-02 took effect for public companies in fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. On January 1, 2019, the Company adopted Topic 842 using the modified retrospective transition method with no impact to stockholders’ equity. As of December 31, 2019, the Company held on its consolidated balance sheet $6,559 for the right-of-use asset and $6,967 for the related lease liability related to operating and finance leases. The difference between the right of use asset and related lease liability is predominantly deferred rent and other related lease expenses under the new lease accounting standard. For additional information regarding how the Company is accounting for leases under Topic 842, refer to Note 13.

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with a forward-looking expected credit loss model which will result in earlier recognition of credit losses. The Company will adopt the new standard effective January 1, 2020 and does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other. This guidance simplifies the accounting for goodwill impairment for all entities by requiring impairment charges to be based on the first step in the current two-step impairment test under ASC 350. The updated standard eliminates the requirement to calculate a goodwill impairment charge using Step 2. If a reporting unit’s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. ASU 2017-04 is effective for reporting periods beginning after December 31, 2019 on a prospective basis, and early adoption is permitted. The Company does not expect ASU 2017-04 to have a material effect on the Company’s financial position, results of operations and cash flows.

In August 2018, the FASB issued ASU 2018-13, Changes to Disclosure Requirements for Fair Value Measurements, which improved the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements. The Company will adopt the new standard effective January 1, 2020 and does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes , which simplifies the accounting for income taxes. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

Revenues

12 Months Ended

Dec. 31, 2019

Revenue from Contract with Customer [Abstract]

Revenues

NOTE 3. REVENUES

On January 1, 2018, the Company adopted ASU 2014-09, using the modified retrospective transition method. There was no effect for any adjustments to retained earnings upon adoption of the standard on January 1, 2018. The Company has two primary streams of revenue: (1) revenue recognized from our sale of products within our pharmacy services and (2) revenue recognized from intellectual property license and asset purchase agreements.

Product Revenues from Pharmacy Services

The Company sells prescription drugs directly through our pharmacy and outsourcing facility network. Revenue from our pharmacy services divisions includes: (i) the portion of the price the client pays directly to us, net of any volume-related or other discounts paid back to the client, (ii) the price paid to us by individuals, and (iii) customer copayments made directly to the pharmacy network. Sales taxes are not included in revenue. Following the core principle of ASU 2014-09, we have identified the following:

1.	Identify the contract(s) with a customer: A contract exists with a customer at the time the prescription or order is received by the Company.
2.	Identify the performance obligations in the contract: The order received contains the performance obligations to be met, in almost all cases the product the customer is wishing to receive. If we are unable to be meet the performance obligation the customer is notified.
3.	Determine the transaction price: the transaction price is based on the product being sold to the customer, and any related customer discounts. These amounts are pre-determined and built into our order management software.
4.	Allocate the transaction price to the performance obligations in the contract: The transaction price associated with the product(s) being ordered is allocated according to the pre-determined amounts.
5.	Recognize revenue when (or as) the entity satisfies a performance obligation: At the time of shipment from the pharmacy or outsourcing facility the performance obligation has been met.

The following revenue recognition policy has been established for the pharmacy services division:

Revenues generated from prescription or office use drugs sold by our pharmacies and outsourcing facility are recognized when the prescription is shipped. At the time of shipment, the pharmacy services division has performed substantially all of its obligations under its client contracts and does not experience a significant level of returns or reshipments. Determination of criteria (3) and (4) is based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. The Company records reductions to revenue for discounts at the time of the initial sale. Estimated returns and allowances and other adjustments are provided for in the same period during which the related sales are recorded and are based on actual returns history. The rate of returns is analyzed annually to determine historical returns experience. If the historical data we use to calculate these estimates do not properly reflect future returns, then a change in the allowance would be made in the period in which such a determination is made and revenues in that period could be materially affected. The Company will defer any revenues received for a product that has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered and no refund will be required.

Intellectual Property License Revenues

The Company currently holds four intellectual property license and related agreements in which the Company has promised to grant a license or sale which provides a customer with the right to access the Company’s intellectual property. License arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple-element arrangements, the revenue of which is recognized at the point of time the performance obligation is met.

Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company’s performance under the other elements of the arrangement. In addition, if the Company’s continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term.

Revenue disaggregated by revenue source for the years ended December 31, 2019 and 2018, consists of the following:

	For the year ended
	December 31,
	2019		2018
Product sales, net	$	51,137	$	41,334
License revenues		28		38
Total revenues	$	51,165	$	41,372

Deferred revenue and customer deposits at December 31, 2019 and 2018, were $57 and $119, respectively. All deferred revenue and customer deposit amounts at December 31, 2018 were recognized as revenue during the year ended December 31, 2019.

Investment in Melt Pharmaceuticals, Inc. and Agreements - Related Party Transactions

12 Months Ended

Dec. 31, 2019

Investments, Debt and Equity Securities [Abstract]

Investment in Melt Pharmaceuticals, Inc. and Agreements - Related Party Transactions

NOTE 4. INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS

In December 2018, the Company entered into an asset purchase agreement with Melt (the “Melt Asset Purchase Agreement”). Pursuant to the terms of the Melt Asset Purchase Agreement, Melt was assigned certain intellectual property and related rights from the Company to develop, formulate, make, sell, and sub-license certain Company conscious sedation and analgesia related formulations (collectively, the “Melt Products”). Under the terms of the Melt Asset Purchase Agreement, Melt is required to make royalty payments to the Company of 5% of net sales of the Melt Products while any patent rights remain outstanding, as well as other conditions. In January and March 2019, the Company entered into the Melt Series A Preferred Stock Agreement, see also Note 2, under the subheading Investment in Melt Pharmaceuticals, Inc.

In February 2019, the Company and Melt entered into a Management Services Agreement (the “Melt MSA”), whereby the Company provides to Melt certain administrative services and support, including bookkeeping, web services and human resources related activities, and Melt pays the Company a monthly amount of $10.

As of December 31, 2019, the Company was due $722 from Melt for reimbursable expenses and amounts due under the Melt MSA and included in prepaid expenses and other current assets on the accompanying consolidated balance sheets. During the year ended December 31, 2019, Melt paid the Company $50.

The Company’s Chief Executive Officer, Mark L. Baum, and Chief Medical Officer, Larry Dillaha, are members of the Melt board of directors, and several employees of the Company (including Mr. Baum, Mr. Dillaha and the Company’s Chief Financial Officer, Andrew Boll) entered into consulting agreements and provide consulting services to Melt.

The unaudited condensed results of operations information of Melt is summarized below:

	For the
	Year Ended
	December 31, 2019
Revenues, net	$	-
Loss from operations		4,169
Net loss	$	(4,169	)

The unaudited condensed balance sheet information of Melt is summarized below:

	December 31, 2019
Current assets	$	7,440
Non current assets		13
Total assets	$	7,453

Total liabilities	$	1,656
Total preferred stock and stockholders’ equity		5,797
Total liabilities and stockholders’ equity	$	7,453

Investment in Surface Pharmaceuticals, Inc. and Agreements - Related Party Transactions

12 Months Ended

Dec. 31, 2019

Investments, Debt and Equity Securities [Abstract]

Investment in Surface Pharmaceuticals, Inc. and Agreements - Related Party Transactions

NOTE 5. INVESTMENT IN SURFACE PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS

In 2017 and amended in April 2018, the Company entered into two asset purchase and license agreements (the “Surface License Agreements”) with its previously wholly owned subsidiary, Surface. Pursuant to the terms of the Surface License Agreements, the Company assigned and licensed to Surface certain intellectual property and related rights associated with Surface’s drug candidates (collectively, the “Surface Products”). Surface is required to make royalty payments to the Company of four to six percent (4%-6%) of net sales of the Surface Products while any patent rights remain outstanding. Certain of the Surface License Agreements were conditioned upon Surface receiving net proceeds of the sale of its equity securities of not less than $10,000, which occurred in May 2018. See also Note 2, under the subheading Investment in Surface Pharmaceuticals, Inc.

In January 2018, the Company and Surface entered into an amended Management Services Agreement (the “MSA”), whereby the Company provided to Surface certain administrative services and support, including bookkeeping, web services and human resources related activities, and Surface paid the Company a monthly amount of $10. The MSA was terminated effective July 31, 2018.

During the year ended December 31, 2019, the Company was paid $50 from Surface for amounts due under the Surface MSA. There are no amounts due from Surface to the Company as of December 31, 2019.

As of December 31, 2019, the Company owned 3,500,000 shares of Surface common stock (approximately 30% of the issued and outstanding equity interests). A Company director, Richard L. Lindstrom, and the Company’s Chief Executive Officer, Mark L. Baum, are directors of Surface. In addition, the Company’s Chief Financial Officer, Andrew R. Boll, was a director of Surface and resigned as a director of Surface concurrent with the sale of the Surface Series A Stock. Several employees and a director of the Company (including Mr. Baum, Dr. Lindstrom and Mr. Boll) entered into consulting agreements and provided consulting services to Surface. Surface is required to make royalty payments to Dr. Lindstrom of 3% of net sales of certain Surface products while certain patent rights remain outstanding. Dr. Lindstrom is also a principal of Flying L Partners, an affiliate of the funding investor who purchased the Surface Series A Stock.

The unaudited condensed results of operations information of Surface is summarized below:

	For the Year Ended			For the Year Ended
	December 31, 2019			December 31, 2018
Revenues, net	$	-		$	-
Loss from operations		4,000			1,370
Net loss	$	(4,000	)	$	(1,370	)

The unaudited condensed balance sheet information of Surface is summarized below:

	At December 31,		At December 31,
	2019		2018
Current assets	$	15,942	$	19,699
Non current assets		47		50
Total assets		15,989		19,749

Total liabilities		619		165
Total stockholders equity		15,370		19,584
Total liabilities and stockholders’ equity	$	15,989	$	19,749

Restricted Cash

12 Months Ended

Dec. 31, 2019

Restricted Cash [Abstract]

Restricted Cash

NOTE 6. RESTRICTED CASH

The restricted cash at December 31, 2019 and 2018 consisted of funds held in a money market account. At December 31, 2019 and 2018, the restricted cash was recorded at amortized cost, which approximates fair value.

At December 31, 2019 and 2018, the funds held in a money market account of $200 were classified as a current asset. The money market account funds are required as collateral as additional security for the Company’s New Jersey facility lease.

Inventories

12 Months Ended

Dec. 31, 2019

Inventory Disclosure [Abstract]

Inventories

NOTE 7. INVENTORIES

Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of December 31, 2019 and 2018 was as follows:

	December 31, 2019		December 31, 2018
Raw materials	$	2,405	$	1,119
Work in progress		20		6
Finished goods		876		709
Total inventories	$	3,301	$	1,834

Prepaid Expenses and Other Current Assets

12 Months Ended

Dec. 31, 2019

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses and Other Current Assets

NOTE 8. PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consisted of the following:

	December 31, 2019		December 31, 2018
Prepaid insurance	$	123	$	328
Other prepaid expenses		358		334
Receivable due from Surface		-		50
Receivable due from Melt		722		-
Deposits and other current assets		105		125
Total prepaid expenses and other current assets	$	1,308	$	837

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

NOTE 9. PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment at December 31, 2019 and 2018 consisted of the following:

	December 31, 2019			December 31, 2018
Property, plant and equipment, net:
Computer software and hardware	$	1,732		$	1,662
Furniture and equipment		363			397
Lab and pharmacy equipment		3,164			3,184
Leasehold improvements		5,510			5,496
		10,769			10,739
Accumulated depreciation and amortization		(5,394	)		(4,364	)
	$	5,375		$	6,375

The Company recorded depreciation and amortization expense of $1,936 and $1,608 during the years ended December 31, 2019 and 2018, respectively.

Intangible Assets and Goodwill

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill

NOTE 10. INTANGIBLE ASSETS AND GOODWILL

The Company’s intangible assets at December 31, 2019 consisted of the following:

	Amortization									Net
	periods			Accumulated						Carrying
	(in years)	Cost		amortization			Impairment			value
Patents	17-19 years	$	1,102	$	(97	)	$	(259	)	$	746
Licenses	20 years		50		(5	)		-			45
Trademarks	Indefinite		340		-			-			340
Customer relationships	3-15 years		3,000		(1,165	)		(630	)		1,205
Trade name	5 years		16		(14	)		(2	)		-
Non-competition clause	3-4 years		294		(274	)		(20	)		-
State pharmacy licenses	25 years		45		(9	)		(35	)		1
		$	4,847	$	(1,564	)	$	(946	)	$	2,337

During the year ended December 31, 2019 the Company incurred impairment charges of $612 related to intangible assets, including customer relationships, trade name, and state pharmacy licenses as a part of the Park Restructuring and $259 of impairment charges related to patents associated with the termination of an asset agreement.

Amortization expense for intangible assets for the year ended December 31 was as follows:

	For the Year Ended		For the Year Ended
	December 31, 2019		December 31, 2018
Patents	$	48	$	28
Licenses		5		-
Customer relationships		151		201
Trade name		1		4
Non-competition clause		-		1
State pharmacy licenses		4		2
	$	209	$	235

Estimated future amortization expense for the Company’s intangible assets at December 31, 2019 is as follows:

Years ending December 31,
2020	$	187
2021		187
2022		187
2023		187
2024		159
Thereafter		1,430
	$	2,337

Changes in the carrying value of the Company’s goodwill during the year ended December 31, 2019 were:

Balance at December 31, 2018	$	2,227
Impairment of Park goodwill (see Note 2)		(1,895	)
Balance at December 31, 2019	$	332

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2019

Payables and Accruals [Abstract]

Accounts Payable and Accrued Expenses

NOTE 11. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses at December 31, 2019 and 2018 consisted of the following:

	December 31, 2019			December 31, 2018
Accounts payable	$	7,409		$	4,966
Other accrued expenses		49			640
Deferred rent		-			388
Accrued interest (see Note 12)		244			256
Accrued exit fee for note payable (see Note 12)		800			800
Total accounts payable and accrued expenses		8,502			7,050
Less: Current portion		(7,702	)		(6,250	)
Non-current total accrued expenses	$	800		$	800

Debt

12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

Debt

NOTE 12. DEBT

SWK Senior Note – 2017

In July 2017, the Company entered into a term loan and security agreement in the principal amount of $16,000 (the “SWK Loan Agreement” or “SWK Loan”) with SWK Funding LLC and its partners (“SWK”), as lender and collateral agent. The SWK Loan Agreement was fully funded at closing with a five-year term, however, such term could be reduced to four years if certain revenue requirements are not achieved. The SWK Loan is secured by nearly all of the Company’s assets, including its intellectual property rights.

Prior to the loan refinance in May 2019 (see below), the SWK Loan was bearing interest at a variable rate equal to the three-month London Inter-Bank Offered Rate (subject to a minimum of 1.50% and maximum of 3.00%), plus an applicable margin of 10.50%. The SWK Loan Agreement permitted the Company to pay interest only on the principal amount loaned thereunder for the first six payments (payments are due on a quarterly basis), which interest-only period could have been reduced to four payments if the Company had not met certain minimum revenue requirements. Following the interest-only period, the Company was required to pay interest, plus repayments of the principal amount loaned under the SWK Loan Agreement, in quarterly payments, which shall not exceed $750 per quarter. All amounts owed under the SWK Loan Agreement, including a final fee equal to 5% of the aggregate principal amount loaned thereunder, were previously due and payable on July 19, 2022. The Company is obligated under the SWK Loan Agreement to pay for certain expenses incurred by the SWK Lender through and after the date of the SWK Loan Agreement, including certain fees and expenses relating to the preparation and administration of the SWK Loan Agreement. The Company incurred expenses and final fee of approximately $1,282 in connection with the SWK Loan Agreement. The final fee and expenses are being amortized as interest expense over the term of the SWK Loan using the effective interest rate method and the related liability of $800 for the final fee is included in accrued expenses (see Note 11) in the accompanying consolidated balance sheets as of December 31, 2019 and 2018.

In connection with the SWK Loan Agreement, the Company issued to SWK warrants to purchase up to 415,586 shares of the Company’s common stock (the “Lender Warrants”) with an exercise price of $3.08. In August 2017, the Company and SWK amended the warrants, to allow for the purchase up to 615,386 warrants with an exercise price of $2.08. The Lender Warrants are exercisable immediately, and have a term of 7 years. The Lender Warrants are subject to a cashless exercise feature, with the exercise price and number of shares issuable upon exercise subject to change in connection with stock splits, dividends, reclassifications and other conditions. The relative fair value of the Lender Warrants was approximately $982 and was estimated using the Black-Scholes-Merton option pricing model with the following assumptions: fair value of the Company’s common stock at issuance of $2.08 per share; seven-year contractual term; 113.5% volatility; 0% dividend rate; and a risk-free interest rate of 1.77%.

SWK Refinance – May 2019

In May 2019, the Company entered into a joinder and amendment (the “Amendment”) to the SWK Loan and SWK, as lender and collateral agent. A summary of the material changes contained in the Amendment are as follows:

	●	The interest rate calculation that the loan bears is now equal to the three-month London Inter-Bank Offered Rate (subject to a minimum of 2.00%), plus an applicable margin of 10.00% (the “Margin Rate”); provided that, if, two days prior to a payment date, the Company provides SWK evidence that the Company has achieved a leverage ratio as of such date of less than 4.00:1:00, the Margin Rate shall equal 9.00%; and if the Company has achieved a leverage ratio as of such date of less than 3.00:1:00, the Margin Rate shall equal 7.00%;

	●	Leverage ratio in the Amendment means, as of any date of determination, the ratio of: (a) indebtedness as of such date to (b) EBITDA (as defined in the SWK Loan), of the Company for the immediately preceding twelve (12) month period, adding-back (i) actual litigation expenses for the immediately preceding twelve (12) month period, minus (ii) actual litigation expenses for the immediately preceding three (3) month period multiplied by four (4);

	●	The definition of the first amortization date was changed to May 14, 2020, permitting the Company to pay interest only on the principal amount loaned for the next four payments (payments are due on a quarterly basis) following the Amendment; and

	●	Subject to the satisfaction of certain revenue and market capitalization requirements and conditions, SWK agreed to make available to the Company an additional principal amount of up to $5,000.

In addition to the terms described above, the Amendment joined the Company’s recently created subsidiaries to the SWK Loan and added definitions related to excluded subsidiaries that are not considered co-borrowers and are subsidiaries of the Company which the Company believes it will eventually deconsolidate from its financials and lose 50% or more of the equity interests of the subsidiary.

Related to the Amendment, the Company incurred expenses related to legal and lender costs of $282 that are included in debt discount and will be amortized over the term of the SWK Loan.

At December 31, 2019, future minimum payments under the Company’s note payable were as follows:

	Amount
2020	$	3,703
2021		4,121
2022		3,828
2023		7,573
Total minimum payments		19,225
Less: amount representing interest		(3,975	)
Notes payable, gross		15,250
Less: unamortized discount		(1,259	)
		13,991
Less: current portion, net of unamortized discount		(1,772	)
Note payable, net of current portion and unamortized debt discount	$	12,219

For the years ended December 31, 2019 and 2018, debt discount amortization related to the note payable was $495 and $520, respectively.

Leases

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Leases

NOTE 13. LEASES

The Company adopted Topic 842 on January 1, 2019. Topic 842 allows the Company to elect a package of practical expedients, which include: (i) an entity need not reassess whether any expired or existing contracts are or contain leases; (ii) an entity need not reassess the lease classification for any expired or existing leases; and (iii) an entity need not reassess any initial direct costs for any existing leases. Another practical expedient allows the Company to use hindsight in determining the lease term when considering lessee options to extend or terminate the lease and to purchase the underlying asset. The Company has elected to utilize the package of practical expedients and has not elected the hindsight methodology in its implementation of Topic 842.

The Company elected to adopt this standard using the modified retrospective transition method and recognized a cumulative-effect adjustment to the consolidated balance sheet on the date of adoption. Comparative periods have not been restated. With the adoption of Topic 842, the Company’s consolidated balance sheet now contains the following line items: Right-of-use assets, Operating lease liabilities—short-term and Operating lease liabilities—long-term.

The Company determined that it held the following significant operating leases of office and laboratory space as of December 31, 2019 (square footage is not described in thousands):

	●	An operating lease for 10,200 square feet of office space in San Diego, California that expires in December 2021, with an option to extend the term for a five-year period;

	●	An operating lease for 4,500 square feet of office and lab space in Irvine, California that expires in December 2020, with an option to extend the term for up to two five-year periods. As part of the Park Restructuring, the Company assessed its obligations under this lease. As of the date of this Annual Report, the Company expects to sublease this space and has determined that there is a practical ability to do so, and as a result did not recognize any impairment costs related to this lease and the Company’s right-to-use asset;

	●	An operating lease for 25,000 square feet of lab, warehouse and office space in Ledgewood, New Jersey that expires in July 2024, with an option to extend the term for two additional five-year periods; and

	●	An operating lease for 5,500 square feet of office space in Nashville, Tennessee that expires in December 2024, with an option to extend the term for two additional five-year periods.

The extensions within the San Diego, California and Ledgewood, New Jersey operating lease agreements were included within the Company’s calculation of the new lease standard as the Company is reasonably certain it will exercise its option to extend these leases. The extensions within the Nashville lease were not included within the Company’s calculation of the new lease standards as the Company is not reasonably certain it will exercise its option to extend that lease. The Company has elected to not recognize right-of-use assets and lease liabilities arising from short-term leases, which are leases that, at the commencement date, have a lease term of 12 months or less and do not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise.

The previously classified capital leases are now classified as finance leases under the new standard. The Company has determined that the identified finance leases did not contain non-lease components and require no further allocation of the total lease cost. The Company has determined that the identified operating leases did contain non-lease components and elected an accounting policy to combine non-lease and lease components to determine the total lease cost. Additionally, the operating agreements in place did not contain information to determine the rate implicit in the leases. As such, the Company calculated the incremental borrowing rate based on the assumed remaining lease term for each lease in order to calculate the present value of the remaining lease payments. At December 31, 2019, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases held by the Company were 6.3% and 10.21 years, respectively.

Upon adoption of Topic 842, the Company recorded a $6,325 increase in operating lease right-of-use assets, a $388 decrease in accounts payable and accrued expenses and a $6,712 increase in operating lease liability. The Company did not record any cumulative effect adjustments to opening stockholders’ equity. In October 2019 the Company signed a new operating lease for 5,500 square feet of office space in Nashville, Tennessee. Upon the execution of the lease, the Company recorded a $753 increase in operating lease right-of-use assets and operating lease liability. As of December 31, 2019, right-of-use assets and liabilities arising from operating leases were $6,559 and $6,967, respectively. During the year ended December 31, 2019, cash paid for amounts included for the operating lease liabilities totaled $905 and the Company recorded operating lease expense of $892 included in selling, general and administrative expenses, respectively.

Future lease payments under operating leases as of December 31, 2019 were as follows:

	Operating Leases
2020	$	1,095
2021		978
2022		998
2023		1,023
2024		1,023
Thereafter		4,465
Total minimum lease payments		9,582
Less: amount representing interest payments		(2,615	)
Total operating lease liabilities		6,967
Less: current portion, operating lease liabilities		(629	)
Operating lease liabilities, net of current portion	$	6,338

The Company also has one additional finance lease that is included in its lease accounting but is not considered significant.

Future lease payments under non-cancelable finance leases as of December 31, 2019 were as follows:

	Finance Lease
2020	$	9
2021		9
2022		9
2023		9
2024		1
Total minimum lease payments		37
Less: amount representing interest payments		(4	)
Present value of future minimum lease payments		33
Less: current portion, finance lease obligation		(7	)
Finance lease obligation, net of current portion	$	26

At December 31, 2019, the weighted average incremental borrowing rate and the weighted average remaining lease term for the finance leases held by the Company were 6.36% and 4.08 years, respectively.

For the year ended December 31, 2019, debt discount amortization related to a finance lease obligation was $17, and included in interest expense, net.

For the year ended December 31, 2019, depreciation expense related to the equipment held under the finance lease obligations was $150.

For the year ended December, 2019, cash paid and expense recognized for interest expense related to finance lease obligations was $18.

Future minimum lease payments under operating leases and future minimum capital lease payments as of December 31, 2018 were as follows:

	Capital Leases			Operating Leases
2019	$	751		$	797
2020		-			857
2021		-			742
2022		-			320
2023		-			330
Thereafter		-			196
	$	751		$	3,242
Less: Amounts representing interest		(15	)
Less: Amounts representing unamortized discount		(16	)
Total obligation under capital leases		720
Less: Current portion of capital leases		(720	)
Long term capital lease obligation	$	-

Stockholders' Equity and Stock-Based Compensation

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Stockholders' Equity and Stock-Based Compensation

NOTE 14. STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION

Common Stock

At December 31, 2019 and 2018, the Company had 50,000,000 shares of common stock, $0.001 par value, authorized, respectively. On July 10, 2018, the Company amended its amended and restated certificate of incorporation to reduce the number of authorized shares of common stock from 90,000,000 to 50,000,000.

Issuances During the Year Ended December 31, 2018

In January 2018, the Company issued 25,273 shares of its restricted common stock, with a fair value of $44, in lieu of a cash payment for accrued royalty expenses.

RSUs granted in February 2015 to Andrew R. Boll, the Company’s Chief Financial Officer, vested, and in February 2018, 30,000 shares the Company’s common stock were issued to Mr. Boll.

RSUs granted in February 2015 to John P. Saharek, the President of ImprimisRx (formerly, the Company’s Chief Commercial Officer), vested, and in February 2018, 30,000 shares the Company’s common stock were issued to Mr. Saharek.

In March 2018, the Company issued 35,427 shares of its restricted common stock, with a fair value of $64, in lieu of a cash payment for accrued royalty expenses.

In December 2018, the Company issued 15,000 shares of its restricted common stock, with a fair value of $42, related to a milestone payment due under a sales and marketing agreement.

The Company sold 305,619 shares of common stock and received net proceeds of $642, after deducting $20 for sales commission and offering expenses, under the Sales Agreement during the year ended December 31, 2018. In November 2018, the Company terminated the Sales Agreement.

During the year ended December 31, 2018, the Company issued 2,364,889 shares of its common stock related to the exercise of common stock warrants with an exercise price of $1.79, and received net proceeds of $4,233.

During the year ended December 31, 2018, the Company issued 910,273 shares of its common stock related to the cashless exercise of 1,576,665 common stock warrants with an exercise price of $1.79.

During the year ended December 31, 2018, 99,626 shares of the Company’s common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until the director resigns.

Issuances During the Year Ended December 31, 2019

In March 2019, the Company issued 15,000 shares of its restricted common stock, with a fair value of $75, as consideration for commission expenses incurred during the year ended December 31, 2018.

During the year ended December 31, 2019, the Company issued 27,671 shares of its common stock upon the cashless exercise of 82,929 options to purchase common stock, with exercise prices ranging from $1.70 to $4.17 per share, net of 8,806 shares of common stock withheld for payroll tax withholdings totaling $50.

During the year ended December 31, 2019, the Company issued 2,122 shares of its common stock upon the exercise of 2,122 options to purchase common stock, with exercise prices ranging from $1.70 to $3.20 per share, and received net proceeds of $6.

During the year ended December 31, 2019, the Company issued 688,473 shares of its common stock upon the cashless exercise of 964,532 warrants to purchase common stock with an exercise price of $1.79 per share.

During the year ended December 31, 2019, the Company issued 454,055 shares of its common stock upon the exercise of 454,055 warrants to purchase common stock with an exercise price of $1.79 per share, and received net proceeds of $813.

During the year ended December 31, 2019, 87,610 shares of the Company’s common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until the director resigns.

Preferred Stock

At December 31, 2019 and 2018, the Company had 5,000,000 shares of preferred stock, $0.001 par value, authorized and no shares of preferred stock issued and outstanding.

Stock Option Plan

On September 17, 2007, the Company’s Board of Directors and stockholders adopted the Company’s 2007 Incentive Stock and Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended, the “2007 Plan”). The 2007 Plan reached its term in September 2017, and we can no longer issue additional awards under this plan, however, options previously issued under the 2007 Plan will remain outstanding until they are exercised, reach their maturity or are otherwise cancelled/forfeited. On June 13, 2017, the Company’s Board of Directors and stockholders adopted the Company’s 2017 Incentive Stock and Awards Plan (the “2017 Plan” together with the 2007 Plan, the “Plans”). As of December 31, 2019, the 2017 Plan provides for the issuance of a maximum of 2,000,000 shares of the Company’s common stock. The purpose of the Plans are to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons in the Company’s development and financial success. Under the Plans, the Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Internal Revenue Code, non-qualified stock options, restricted stock units and restricted stock. The Plans are administered by the Compensation Committee of the Company’s Board of Directors. The Company had 1,004,656 shares available for future issuances under the 2017 Plan at December 31, 2019.

Stock Options

A summary of stock option activity under the Plan for the year ended December 31, 2019 is as follows:

	Number of shares			Weighted Avg. Exercise Price		Weighted Avg. Remaining Contractual Life		Aggregate Intrinsic Value
Options outstanding - January 1, 2019		2,482,009		$	5.09
Options granted		362,000		$	6.19
Options exercised		(85,051	)	$	3.56
Options cancelled/forfeit		(102,275	)	$	4.67
Options outstanding - December 31, 2019		2,656,683		$	5.31		5.05	$	7,011
Options exercisable		1,603,530		$	4.57		5.72	$	5,552
Options vested and expected to vest		2,558,998		$	5.26		5.10	$	6,911

The aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option holders if all option holders had exercised and immediately sold all options with an exercise price lower than the market price on December 31, 2019, based on the closing price of the Company’s common stock of $7.78 on that date.

The intrinsic value of the options exercised in 2019 was $246.

During 2019 and 2018, the Company granted stock options to certain employees, directors and consultants. The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms ranging from five to ten years. Vesting terms for options granted in 2019 and 2018 to employees and consultants typically included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; quarterly vesting over three years; and 90% of the shares subject to the option vest and become exercisable on the second month after the grant date and the remaining 10% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over the next 11 months. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plan) and in the event of certain modifications to the option award agreement.

The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. Beginning on April 1, 2018, the Company began calculating expected volatility based solely on the historical volatilities of the common stock of the Company. In the past, the expected volatility was based on the historical volatilities of the common stock of the Company and comparable publicly traded companies, the Company previously utilized this methodology based on its estimate that it had limited relevant historical data regarding the volatility of its stock price on which to base a meaningful estimate of expected volatility. The expected volatility is based on the historical volatilities of the common stock of the Company and comparable publicly traded companies based on the Company’s belief that it currently has limited relevant historical data regarding the volatility of its stock price on which to base a meaningful estimate of expected volatility. The expected term of options granted was determined in accordance with the “simplified approach,” as the Company has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of 10%. These factors could change in the future, which would affect the determination of stock-based compensation expense in future periods. Utilizing these assumptions, the fair value is determined at the date of grant.

The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees:

	2019			2018
Weighted-average fair value of options granted	$	3.72		$	1.42
Expected terms (in years)		5.07 - 7.00			5.77 - 6.11
Expected volatility		64 - 78	%		76 - 126	%
Risk-free interest rate		1.83 – 2.68	%		2.05 – 3.00	%
Dividend yield		-			-

The following table summarizes information about stock options outstanding and exercisable at December 31, 2019:

			Weighted
			Average		Weighted				Weighted
			Remaining		Average				Average
	Number		Contractual		Exercise		Number		Exercise
Range of Exercise Prices	Outstanding		Life in Years		Price		Exercisable		Price
$1.47 - $2.60		781,940		6.66	$	2.05		619,016	$	2.10
$3.04 - $4.50		458,622		6.09	$	3.96		440,124	$	3.98
$5.49 - $6.36		440,350		7.91	$	6.15		178,619	$	6.08
$6.64 - $8.99		970,741		1.99	$	8.01		360,741	$	8.24
$42.80		5,030		0.62	$	42.80		5,030	$	42.80
$1.47 - $42.80		2,656,683		5.05	$	5.31		1,603,530	$	4.57

As of December 31, 2019, there was approximately $3,848 of total unrecognized compensation expense related to unvested stock options granted under the Plan. That expense is expected to be recognized over the weighted-average remaining vesting period of 1.37 years. The stock-based compensation for all stock options was $889 and $1,317 during the years ended December 31, 2019 and 2018, respectively.

Restricted Stock Units

RSU awards are granted subject to certain vesting requirements and other restrictions, including performance and market based vesting criteria. The grant-date fair value of the RSUs, which has been determined based upon the market value of the Company’s common stock on the grant date, is expensed over the vesting period of the RSUs. Unvested portions of RSUs issued to consultants are remeasured on an interim basis until vesting criteria is met.

Grants During the Year Ended December 31, 2018

During the year ended December 31, 2018, the Company granted an aggregate of 136,360 RSUs to its non-employee directors valued at $300. These RSUs vest in equal quarterly installments over a one-year period subject to the director’s continued service at the vesting date, but the issuance and delivery of these shares are deferred until the director resigns.

A summary of the Company’s RSU activity and related information for the year ended December 31, 2018 is as follows:

	Number of RSUs			Weighted Average Grant Date Fair Value
RSUs unvested - January 1, 2018		1,298,946		$	2.42
RSUs granted		136,360		$	2.20
RSUs vested		(159,626	)	$	3.94
RSUs cancelled/forfeit		-
RSUs unvested at December 31, 2018		1,275,680		$	2.16

Grants During the Year Ended December 31, 2019

During the year ended December 31, 2019, 185,000 RSUs with a fair market value of $1,139 were issued to certain employees; the RSUs vest in full on the third anniversary of the grant date.

During the year ended December 31, 2019, the Company’s board of directors were granted 38,860 RSUs with a fair market value $300 which vests on a quarterly basis, over one year in equal installments, subject to the director’s continued service at the vesting date, but the issuance and delivery of these shares are deferred until the director resigns.

A summary of the Company’s RSU activity and related information for the year ended December 31, 2019 is as follows:

	Number of RSUs			Weighted Average Grant Date Fair Value
RSUs unvested - January 1, 2019		1,275,680		$	2.16
RSUs granted		223,860		$	6.43
RSUs vested		(87,610	)	$	3.42
RSUs cancelled/forfeit		-
RSUs unvested at December 31, 2019		1,411,930		$	2.76

As of December 31, 2019, the total unrecognized compensation expense related to unvested RSUs was approximately $1,031 which is expected to be recognized over a weighted-average period of 0.3 years, based on estimated vesting schedules. The stock-based compensation for RSUs was $879 and $1,149 during the years ended December 31, 2019 and 2018, respectively.

Subsidiary Stock-Based Transactions

Surface Pharmaceuticals, Inc. and Melt Pharmaceuticals, Inc. – 2018

During the year ended December 31, 2018 the Company recognized $21 in stock-based compensation related to equity instruments granted by Surface and Melt to consultants, the Company’s employees and directors, including its CEO, Mark Baum, CFO, Andrew Boll, and a director, Richard Lindstrom.

Mayfield Pharmaceuticals, Inc. - 2019

Mayfield issued 1,000,000 shares of its common stock to Elle in connection with acquisition of certain drug candidate intellectual property and rights in February 2019.

Mayfield issued 300,000 shares of its common stock to TGV in connection with acquisition of certain drug candidate intellectual property and rights in July 2019.

During the year ended December 31, 2019, the Company recognized $26 in stock-based compensation related to equity instruments granted by Mayfield for 2,450,000 shares of its restricted common stock that vest upon various performance based milestones and service periods to consultants of Mayfield, including Mayfield’s CEO candidate and to Harrow employees, including 725,000 shares to Mark Baum, CEO of the Company, and 362,500 shares to Andrew Boll, CFO of the Company.

Stowe Pharmaceuticals, Inc. - 2019

In July 2019, Stowe agreed to issue 1,750,000 shares of its common stock to TGV in connection with acquisition of certain drug candidate intellectual property and rights.

The Company recorded stock-based compensation (including issuance of common stock for services and accrual for stock-based compensation) related to equity instruments granted to employees, directors and consultants as follows:

	For the Year Ended		For the Year Ended
	December 31, 2019		December 31, 2018
Employees – selling, general and administrative	$	1,464	$	2,251
Directors – selling, general and administrative		300		235
Consultants - selling general and administrative		259		150
Total	$	2,023	$	2,636

Warrants

From time to time, the Company issues warrants to purchase shares of the Company’s common stock to investors, lenders (see Note 12), underwriters and other non-employees for services rendered or to be rendered in the future.

A summary of warrant activity during the year ended December 31, 2019 is as follows:

	Number of Shares Subject to Warrants Outstanding			Weighted Avg. Exercise Price

Warrants outstanding - January 1, 2019		2,206,973		$	1.91
Granted		-
Exercised		(1,418,587	)	$	1.79
Expired		(8,000	)	$	1.79
Warrants outstanding and exercisable - December 31, 2019		780,386		$	2.12
Weighted average remaining contractual life of the outstanding warrants in years - December 31, 2019		4.53

All warrants outstanding as of December 31, 2019 are included in the following table:

	Warrants Outstanding					Warrants Exercisable
		Warrants		Exercise		Warrants		Expiration
Warrant Series	Issue Date	Outstanding		Price		Exercisable		Date
Lender warrants	5/11/2015		125,000	$	1.79		125,000		5/11/2025
Settlement warrants	8/16/2016		40,000	$	3.75		40,000		8/16/2021
Lender warrants (see Note 12)	7/19/2017		615,386	$	2.08		615,386		7/19/2024
			780,386	$	2.12		780,386

Income Taxes

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

NOTE 15. INCOME TAXES

The Company is subject to taxation in the United States, California, New Jersey, Texas and Pennsylvania. The provision for income taxes for the years ended December 31, 2019 and 2018 are summarized below:

	December 31, 2019			December 31, 2018
Current:
Federal	$	-		$	-
State		8			6
Total current	$	8		$	6

Deferred:
Federal	$	669		$	3,294
State		(148	)		440
Change in valuation allowance		(521	)		(3,734	)
Total deferred		0			0
Income tax provision (benefit)	$	8		$	6

Income tax expense for the years ended December 31, 2019 and 2018, are recorded in the general and administrative expenses line item in the accompanying consolidated statements of operations.

A reconciliation of income taxes computed by applying the statutory U.S. income tax rate to the Company’s loss before income taxes to the income tax provision is as follows:

	December 31, 2019			December 31, 2018
U.S. federal statutory tax rate		21.00	%		21.00	%
Benefit of lower tax brackets		0.00	%		0.00	%
State tax benefit, net		(6.73	)%		0.04	%
Research and development credits		0.00	%		(0.14	)%
Employee stock-based compensation		3.10	%		0.46	%
Loss on debt conversion		0.00	%		0.00	%
Capitalization of Subsidiary		0.00	%		0.00	%
Change in Rate		0.00	%		0.00	%
Other		(358.67	)%		0.13	%
Valuation allowance		334.57	%		(21.93	)%
Effective income tax rate		(6.73	)%		(0.44	)%

Deferred tax assets and liabilities reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:

	December 31, 2019			December 31, 2018
Deferred tax assets (liabilities):
NOLs	$	19,827		$	19,726
Depreciation and amortization		224			30
Other		640			604
Research and development credits		596			617
Deferred stock compensation		3,533			3,036
Basis Difference in Melt		(1,185	)		-
Basis Difference in Surface		(1,119	)		(1,464	)
Basis Difference in Eton		(7,528	)		(6,340	)
Capital Losses		62			-
Park stock purchase identifiable intangibles		(270	)		(484	)
Limitation Under 163(j)		299			-
ASC 842 Lease Liability		2,082			-
ASC 842 ROU Asset		(1,959	)		-
Total deferred tax assets, net		15,202			15,723
Valuation allowance		(15,202	)		(15,723	)
Net deferred tax liabilities	$	-		$	-

Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance decreased by approximately $500 and $3,700 during 2019 and 2018, respectively.

As of December 31, 2019, the Company had net operating loss carryforwards for federal income tax purposes of approximately $65,874 and federal research and development tax credits of approximately $354. Under new tax law, federal NOLs can be carried forward indefinitely. The federal research credits will expire beginning in the year 2026. As of December 31, 2019, the Company had net operating loss carryforwards for state income tax purposes of approximately $67,538 which expire beginning in the year 2017 and state research and development tax credits of approximately $305 which do not expire.

In March 2016, the FASB issued ASU 2016-09, Improvement to Employee Share – Based Payment Accounting. The new standard contains several amendments that will simplify the accounting for employee share-based payment transactions. The changes in the new standard eliminate the accounting for excess tax benefits to be recognized in additional paid-in capital and tax deficiencies recognized either in income tax provision or in additional paid-in capital. The Company’s deferred tax asset at December 31, 2018 did not include any excess tax benefits from employee stock option exercises, which are a component of the federal and state net operating loss carryforwards and on a go forward basis the excess tax benefits will be recognized as a component of income tax expense.

Utilization of the net operating losses may be subject to substantial annual limitation due to federal and state ownership change limitations provided by the Internal Revenue Code and similar state provisions. Such annual limitations could result in the expiration of the net operating losses ad credits before their utilization.

In June 2006, the FASB issued interpretation ASC 740-10-50, Accounting for Uncertainty in Income Tax. This pronouncement clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with ASC 740-10-50, Accounting for Income Taxes. This interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in the tax return. ASC 740 also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transaction. The Company adopted ASC 740-10-50 effective January 1, 2009. In accordance with ASC 740-10-50, the Company is classifying interest and penalties as a component of tax expense.

The Company did not have any unrecognized tax benefits as of December 31, 2019 and 2018, all of which is offset by a full valuation allowance. These unrecognized tax benefits, if recognized, would not affect the effective tax rate. There was no interest or penalties accrued at the adoption date and at December 31, 2019.

A reconciliation of the change in the UTB balance from January 1, 2019 to December 31, 2019 is as follows:

	Fed & State Tax
Balance at January 1, 2019	$	-
Additions for tax positions related to current year		-
Additions/(reductions) for tax positions related to prior years		-

Balance at December 31, 2019		-

Total unrecognized tax benefits as of December 31, 2019		-

Employee Savings Plan

12 Months Ended

Dec. 31, 2019

Retirement Benefits [Abstract]

Employee Savings Plan

NOTE 16. EMPLOYEE SAVINGS PLAN

The Company has established an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code, effective January 1, 2014. The plan allows participating employees to deposit into tax deferred investment accounts up to 100% of their salary, subject to annual limits. The Company makes certain matching contributions to the plan in amounts up to 4% of the participants’ annual cash compensation, subject to annual limits. The Company contributed approximately $312 and $248 to the plan during the years ended December 31, 2019 and 2018, respectively.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 17. COMMITMENTS AND CONTINGENCIES

Legal

Dr. Sobol

In December 2016, Louis L. Sobol, M.D. (“Sobol”) filed a lawsuit in the U.S. District Court for the Eastern District of Michigan, Southern Division against the Company, asserting claims on behalf of himself and an as-yet-uncertified class of consumers. The claims allege violations under the Telephone Consumer Protection Act, 47 U.S.C. § 227 via the Company’s alleged transmittal of advertisements to its clients via facsimile. The Court approved the parties’ proposed settlement agreement in the spring of 2019. During the year ended December 31, 2018, the Company accrued $640 for expected damages related to this matter and the proposed settlement amount. As a result of the low claim rate of approximately 1.4%, the Company’s total damages were $571, which was paid in October 2019. This formally resolved all known disputes between the parties.

Allergan USA

In September 2017, Allergan USA, Inc. (“Allergan”) filed a lawsuit in the U.S. District Court for the Central District of California against the Company, primarily claiming violations under the federal Lanham Act and California’s Sherman Act. The Court granted in part and denied in part each parties’ motions for summary judgement, resolving all issues except for whether Allergan was entitled to damages related to the Company’s purported Lanham Act violations. The parties went to trial in May 2019 to litigate damages related to the Lanham Act, and a jury found the Company liable for only $49 in lost profit damages, which was accrued as an expense during the period ended December 31, 2019 (see Note 11). In July 2019, the Court entered a permanent injunction, the scope of which is limited to compounded drugs prepared in, dispensed from within, or shipped to the state of California. The injunction requires the Company to: (1) only dispense drugs from a 503(a) facility with a “Valid Prescription Order”; (2) abide by the FDA’s anticipatory compounding guidelines; and (3) only use bulk drug substances identified on a list established by the Secretary of Health and Human Services or FDA’s interim “Category 1” list. The Company believes it was already in compliance with the order, prior to the injunction being ordered. On October 2, 2019, Allergan and the Company filed a joint stipulation to voluntarily dismiss each parties’ respective pending appeals arising out of the lawsuit. No economic consideration was exchanged between the parties related to the filing of the joint stipulation. This formally resolved all known disputes between the parties.

California Board of Pharmacy

In March 2018, the California Board of Pharmacy filed an accusation against Park related to a compounded formulation the Company believes was legally dispensed and was, without its knowledge, inappropriately administered to a patient unknown to Park, by the prescribing healthcare professional. Park filed a response to the accusation and requested a formal hearing. In April 2019, Park agreed to, and the California State Board of Pharmacy approved terms of a settlement agreement (the “Settlement Agreement”) that became effective on May 29, 2019. Pursuant to the terms of the Settlement Agreement, Park was required to, and did, surrender its California pharmacy license by August 27, 2019. This formally resolved all known disputes between the parties.

Novel Drug Solutions et al.

In April 2018, Novel Drug Solutions, LLC and Eyecare Northwest, PA (collectively “NDS”) filed a lawsuit against the Company in the U.S. District Court of Delaware asserting claims for breach of contract. The claims stem from an asset purchase agreement between the Company and NDS entered into in 2013. In July 2019, NDS filed a second amended complaint which added a claim related to its purported termination of the APA. In October 2019, NDS voluntarily dismissed all claims related to breach of contract, leaving only claims related to the scope of the post-termination obligations to be litigated. The Company believes the claims are meritless and has previously and will continue to dispute all claims asserted against it and intends to vigorously defend against these allegations. Nonetheless, the Company cannot predict the eventual outcome of this litigation and, it could result in substantial costs, losses and a diversion of management’s resources and attention, which could harm the Company’s business and the value of its common stock.

Product and Professional Liability

Product and professional liability litigation represents an inherent risk to all firms in the pharmaceutical and pharmacy industry. We utilize traditional third-party insurance policies with regard to our product and professional liability claims. Such insurance coverage at any given time reflects current market conditions, including cost and availability, when the policy is written.

John Erick et al.

In January 2018, John Erick and Deborah Ferrell, successors-in-interest and heirs of Jade Erick, (collectively “Erick”) filed a lawsuit in the San Diego County Superior against Kim Kelly, ND, MPH asserting claims related to death of Jade Erick. In April 2018, Erick filed an amendment to the lawsuit, naming us as a co-defendant. In September 2018, co-defendant Dr. Kelly filed a cross-complaint against the Company and various entities affiliated with Spectrum Laboratory Products, Inc., Spectrum Chemical Manufacturing Corp. and Spectrum Pharmacy Products, Inc. (collectively “Spectrum”). The cross-complaint seeks indemnity and contribution from the Company and Spectrum. The Company answered the claims filed by Dr. Kelly in October 2018. The case is currently in the discovery phase. The Company believes the claims are meritless and has previously and will continue to dispute all claims asserted against it and intends to vigorously defend against these allegations. Nonetheless, the Company cannot predict the eventual outcome of this litigation, it could result in substantial costs, losses and a diversion of management’s resources and attention, which could harm the Company’s business and the value of its common stock.

Anna Sue Gaukel et al.

In June 2019, Anna Sue Gaukel and Lawrence Gaukel served the Company with a lawsuit filed in state court in Idaho against Imprimis Pharmaceuticals, Inc. asserting class action allegations and product liability claims related to Mrs. Gaukel’s doctor’s use of a compounded drug injection in each of her eyes. In June 2019, the Company removed the case to Federal Court and subsequently answered the complaint. On January 24, 2020, the plaintiffs and the Company filed a joint stipulation, and the case was dismissed with prejudice. No economic consideration was exchanged between the parties related to the filing of the joint stipulation. This formally resolved all known disputes between the parties as connected to this matter.

General and Other

In the ordinary course of business, the Company may face various claims brought by third parties and it may, from time to time, make claims or take legal actions to assert its rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject the Company to litigation.

Indemnities

In addition to the indemnification provisions contained in the Company’s charter documents, the Company generally enters into separate indemnification agreements with each of the Company’s directors and officers. These agreements require the Company, among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys’ fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual’s status or service as the Company’s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification by the Company. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying consolidated balance sheets.

Sales and Marketing Agreements

During 2017 through 2019, the Company entered various sales and marketing agreements with certain organizations, to provide sales and marketing representation services to ImprimisRx in select geographies in the U.S., in connection with the Company’s ophthalmic compounded formulations.

Under the terms of the sales and marketing agreements, the Company is required to make commission payments to equal to 10% - 14% of net sales for products above and beyond the initial existing sales amounts. In addition, the Company is required to make periodic milestone payments to certain organizations in shares of the Company’s restricted common stock if net sales in the assigned territory reach certain future levels by the end of their terms, as applicable. The Company accrued and recorded in additional paid in capital $159 and $42 related to stock-based payments for these agreements during the year ended December 31, 2019 and 2018, respectively, and $2,700 and $1,511 were incurred under these agreements for commission expenses during the years ended December 31, 2019 and 2018, respectively.

Asset Purchase, License and Related Agreements

The Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors and related parties (the “Inventors”) through multiple asset purchase agreements, license agreements, strategic agreements and commission agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research, develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right of first refusal on additional intellectual property and drug development opportunities presented by these Inventors.

In consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the first investigational new drug application (“IND”) with the FDA for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company’s development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors. $371 and $245 were accrued in accounts payable and accrued expenses under these agreements during the years ended December 31, 2019 and 2018, respectively, and $846 and $561 were incurred under these agreements as royalty expenses for the years ended December 31, 2019 and 2018, respectively.

Mayfield License

In July 2019, Mayfield entered into a License Agreement (the “TGV License”) with TGV to acquire intellectual property rights for use in the women’s health field, related to Mayfield’s proprietary drug candidate MAY-66. The TGV License provides that TGV will cooperate with Mayfield in transferring all embodiments of the intellectual property (including know-how) related to the TGV License, assist in obtaining and protecting its patent rights for the acquired intellectual property and that Mayfield will use commercially reasonable efforts to research, develop and commercialize products based on the acquired intellectual property. In connection with the TGV License, Mayfield is obligated to make royalty payments to TGV equal to a low single digit percentage of net sales received by Mayfield in connection with the sale or licensing of any product based on the licensed intellectual property. In addition, Mayfield issued 300,000 shares of its common stock to TGV and is required to make certain milestone payments to TGV over the development of MAY-66 and any related products based on the licensed intellectual property.

Stowe License

In July 2019, Stowe entered into a License Agreement (the “Stowe License”) with TGV, to acquire intellectual property rights for use in the ophthalmology and otic health field, related to Stowe’s proprietary drug candidate STE-006. The Stowe License provides that TGV will cooperate with Stowe in transferring all embodiments of the intellectual property (including know-how) related to the Stowe License, assist in obtaining and protecting its patent rights for the acquired intellectual property and that Stowe will use commercially reasonable efforts to research, develop and commercialize products based on the acquired intellectual property. In connection with the Stowe License, Stowe is obligated to make royalty payments to TGV equal to a low single digit percentage of net sales received by Stowe in connection with the sale or licensing of any product based on the licensed intellectual property. In addition, Stowe issued 1,750,000 shares of its common stock to TGV and is required to make certain milestone payments to TGV over the development of STE-006 and any related products based on the licensed intellectual property.

Klarity License Agreement – Related Party

In April 2017, the Company entered into a license agreement (the “Klarity License Agreement”) with Richard L. Lindstrom, M.D., a member of its Board of Directors. Pursuant to the terms of the Klarity License Agreement, the Company licensed certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license the topical ophthalmic solution Klarity designed to protect and rehabilitate the ocular surface (the “Klarity Product”).

Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold. In addition, the Company is required to make certain milestone payments to Dr. Lindstrom including: (i) an initial payment of $50 upon execution of the Klarity License Agreement, (ii) a second payment of $50 following the first $50 in net sales of the Klarity Product; and (iii) a final payment of $50 following the first $100 in net sales of the Klarity Product. All of the above referenced milestone payments were payable at the Company’s election in cash or shares of the Company’s restricted common stock. Dr. Lindstrom was paid $63 and $122 in cash during the years ended December 31, 2019 and 2018, respectively, and was due an additional $55 and $15 at December 31, 2019 and 2018, respectively. The Company incurred $103 and $118 for royalty expenses related to the Klarity License Agreement during the years ended December 31, 2019 and 2018, respectively.

Injectable Asset Purchase Agreement – Related Party

In December 2019, the Company entered into an asset purchase agreement (the “Lindstrom APA”) with Dr. Lindstrom, a member of its Board of Directors. Pursuant to the terms of the Lindstrom APA, the Company acquired certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic injectable product (the “Lindstrom Product”).

Under the terms of the Lindstrom APA, the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold. In addition, the Company is required to make certain milestone payments to Dr. Lindstrom including an initial payment of $33 upon execution of the Lindstrom APA. Dr. Lindstrom was paid $0 in cash during the year ended December 31, 2019, and was due $40 at December 31, 2019. The Company incurred $40 for royalty expenses related to the Lindstrom Agreement during the year ended December 31, 2019.

Presbyopia Asset Purchase Agreement – Related Party

In December 2019, the Company entered into an asset purchase agreement (the “Presbyopia APA”) with Dr. Lindstrom, a member of its Board of Directors. Pursuant to the terms of the Presbyopia APA, the Company acquired certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic topical product to treat presbyopia (the “Presbyopia Product”).

Under the terms of the Presbyopia Product, the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net sales, dependent upon the final formulation and patent protection of the Presbyopia Product sold. Dr. Lindstrom was paid $0 in cash during the year ended December 31, 2019, and was due $0 at December 31, 2019. The Company incurred $0 for royalty expenses related to the Presbyopia APA during the year ended December 31, 2019.

Segment Information and Concentrations

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Segment Information and Concentrations

NOTE 18. SEGMENT INFORMATION AND CONCENTRATIONS

Beginning on January 1, 2019, the Company began evaluating performance of the Company based on operating segments. Segment performance for its two operating segments are based on segment contribution. The Company’s reportable segments consist of (i) its commercial stage pharmaceutical compounding business (Pharmaceutical Compounding), generally including the operations of ImprimisRx and the former Park businesses; and (ii) its start-up operations associated with pharmaceutical drug development business (Pharmaceutical Drug Development). Segment contribution for the segments represents net revenues less cost of sales, research and development, selling and marketing expenses, and select general and administrative expenses. The Company does not evaluate the following items at the segment level:

	●	Selling, general and administrative expenses that result from shared infrastructure, including certain expenses associated with legal matters, public company costs (e.g. investor relations), board of directors and principal executive officers and other like shared expenses.

	●	Operating expenses within selling, general and administrative expenses that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, acquisition and other shared costs.

	●	Other select revenues and operating expenses including R&D expenses, amortization, and asset sales and impairments, net as not all such information has been accounted for at the segment level, or such information has not been used by all segments.

	●	Total assets including capital expenditures.

The Company defines segment net revenues as pharmaceutical compounded drug sales, licenses and other revenue derived from related agreements.

Cost of sales within segment contribution includes direct and indirect costs to manufacture formulations and sell products, including active pharmaceutical ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs, manufacturing equipment and tenant improvements depreciation, the write-off of obsolete inventory and other related expenses.

Selling, general and administrative expenses consist mainly of personnel-related costs, marketing and promotion costs, distribution costs, professional service costs, insurance, depreciation, facilities costs, transaction costs, and professional services costs which are general in nature and attributable to the segment.

Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the year ended December 31, 2019:

	For the Year Ended December 31, 2019
	Pharmaceutical			Pharmaceutical
	Compounding			Drug Development			Total
Net revenues	$	51,165		$	-		$	51,165
Cost of sales		(16,749	)		-			(16,749	)
Gross profit		34,416			-			34,416

Operating expenses:
Selling, general and administrative		24,468			174			24,642
Research and development		1,006			361			1,367
Segment contribution	$	8,942		$	(535	)	$	8,407
Corporate								8,245
Research and development								716
Amortization								209
Asset sales and impairments, net								4,040
Operating loss							$	(4,803	)

The Company categorizes revenues by geographic area based on selling location. All operations are currently located in the U.S.; therefore, total revenues are attributed to the U.S. All long-lived assets at December 31, 2019 and December 31, 2018 are located in the U.S.

The Company sells its compounded formulations to a large number of customers. There were no customers who comprised more than 10% of the Company’s total pharmacy sales for the year ended December 31, 2019 and 2018.

The Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for 73% of active pharmaceutical ingredient purchases during the year ended December 31, 2019, and 51% during the year ended December 31, 2018.

Subsequent Events

12 Months Ended

Dec. 31, 2019

Subsequent Events [Abstract]

Subsequent Events

NOTE 19. SUBSEQUENT EVENTS

The Company has performed an evaluation of events occurring subsequent to December 31, 2019 through the filing date of this Annual Report and determined that no subsequent events have occurred that would require recognition in the financial statements or disclosures in the notes thereto.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Use of Estimates

Use of Estimates

Liquidity

Liquidity

Segments

Segments

Noncontrolling Interests

Noncontrolling Interests

	(1)	net income or loss;
	(2)	transactions with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and
	(3)	each component of other income or loss.

Revenue Recognition and Deferred Revenue

Revenue Recognition and Deferred Revenue

Cost of Sales

Cost of Sales

Research and Development

Research and Development

Debt Issuance Costs and Debt Discount

Debt Issuance Costs and Debt Discount

Intellectual Property

Intellectual Property

Income Taxes

Income Taxes

Cash and Cash Equivalents

Cash and Cash Equivalents

Cash equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition.

Concentrations of Credit Risk

Concentrations of Credit Risk

Investment in Eton Pharmaceuticals, Inc.

Investment in Eton Pharmaceuticals, Inc.

Mark L. Baum, the Company’s Chief Executive Officer is a member of the Eton board of directors.

Accounts Receivable

Accounts Receivable

Inventories

Inventories

Investment in Melt Pharmaceuticals, Inc.

Investment in Melt Pharmaceuticals, Inc.

See Note 4 for more information and related party disclosure regarding Melt.

Investment in Surface Pharmaceuticals, Inc.

Investment in Surface Pharmaceuticals, Inc.

See Note 5 for more information and related party disclosure regarding Surface.

Property, Plant and Equipment

Property, Plant and Equipment

Business Combinations

Business Combinations

	●	future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and

	●	discount rates utilized in valuation estimates.

Goodwill and Intangible Assets

Goodwill and Intangible Assets

	●	significant underperformance of the Company’s business relative to expected operating results;

	●	significant adverse economic and industry trends;

	●	significant decline in the Company’s market capitalization for an extended period of time relative to net book value; and

	●	expectations that a reporting unit will be sold or otherwise disposed.

The goodwill impairment test consists of a two-step process as follows:

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Park Restructuring

Park Restructuring

Fair Value Measurements

Fair Value Measurements

●	Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.
●	Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
●	Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.

Stock-Based Compensation

Stock-Based Compensation

Basic and Diluted Net Income Per Common Share

Basic and Diluted Net Income per Common Share

The following table shows the computation of basic net income per share of common stock for the years ended December 31, 2019 and 2018:

	For the		For the
	Year Ended		Year Ended
	December 31, 2019		December 31, 2018

Numerator – net income	$	168	$	14,625
Denominator – weighted average number of shares outstanding, basic		25,323,159		21,917,570
Net income per share, basic	$	0.01	$	0.67

	For the Year Ended		For the Year Ended
	December 31, 2019		December 31, 2018
	Shares		Shares
Diluted shares related to:		25,323,159		21,917,570
Warrants		488,498		1,844,272
Stock options		654,441		50,203
Dilutive common equivalent shares		26,466,098		23,812,045

	For the		For the
	Year Ended		Year Ended
	December 31, 2019		December 31, 2018

Numerator – net income	$	168	$	14,625
Weighted average number of shares outstanding, basic		25,323,159		21,917,570
Dilutive common equivalents		1,142,939		1,894,475
Denominator – number of shares used for diluted earnings per share computation		26,466,098		23,812,045
Net income per share, diluted	$	0.01	$	0.61

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Schedule of Basic Earnings Per Common Share

The following table shows the computation of basic net income per share of common stock for the years ended December 31, 2019 and 2018:

	For the		For the
	Year Ended		Year Ended
	December 31, 2019		December 31, 2018

Numerator – net income	$	168	$	14,625
Denominator – weighted average number of shares outstanding, basic		25,323,159		21,917,570
Net income per share, basic	$	0.01	$	0.67

Schedule of Diluted Common Equivalent Shares

	For the Year Ended		For the Year Ended
	December 31, 2019		December 31, 2018
	Shares		Shares
Diluted shares related to:		25,323,159		21,917,570
Warrants		488,498		1,844,272
Stock options		654,441		50,203
Dilutive common equivalent shares		26,466,098		23,812,045

Schedule of Diluted Earnings Per Common Share

	For the		For the
	Year Ended		Year Ended
	December 31, 2019		December 31, 2018

Numerator – net income	$	168	$	14,625
Weighted average number of shares outstanding, basic		25,323,159		21,917,570
Dilutive common equivalents		1,142,939		1,894,475
Denominator – number of shares used for diluted earnings per share computation		26,466,098		23,812,045
Net income per share, diluted	$	0.01	$	0.61

Revenues (Tables)

12 Months Ended

Dec. 31, 2019

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregated Revenue

Revenue disaggregated by revenue source for the years ended December 31, 2019 and 2018, consists of the following:

	For the year ended
	December 31,
	2019		2018
Product sales, net	$	51,137	$	41,334
License revenues		28		38
Total revenues	$	51,165	$	41,372

Investment in Melt Pharmaceuticals, Inc. and Agreements - Related Party Transactions (Tables) - Melt Pharmaceuticals [Member]

12 Months Ended

Dec. 31, 2019

Schedule of Condensed Income Statement

The unaudited condensed results of operations information of Melt is summarized below:

	For the
	Year Ended
	December 31, 2019
Revenues, net	$	-
Loss from operations		4,169
Net loss	$	(4,169	)

Schedule of Condensed Balance Sheet

The unaudited condensed balance sheet information of Melt is summarized below:

	December 31, 2019
Current assets	$	7,440
Non current assets		13
Total assets	$	7,453

Total liabilities	$	1,656
Total preferred stock and stockholders’ equity		5,797
Total liabilities and stockholders’ equity	$	7,453

Investment in Surface Pharmaceuticals, Inc. and Agreements - Related Party Transactions (Tables) - Surface Pharmaceuticals, Inc [Member]

12 Months Ended

Dec. 31, 2019

Schedule of Condensed Income Statement

The unaudited condensed results of operations information of Surface is summarized below:

	For the Year Ended			For the Year Ended
	December 31, 2019			December 31, 2018
Revenues, net	$	-		$	-
Loss from operations		4,000			1,370
Net loss	$	(4,000	)	$	(1,370	)

Schedule of Condensed Balance Sheet

The unaudited condensed balance sheet information of Surface is summarized below:

	At December 31,		At December 31,
	2019		2018
Current assets	$	15,942	$	19,699
Non current assets		47		50
Total assets		15,989		19,749

Total liabilities		619		165
Total stockholders equity		15,370		19,584
Total liabilities and stockholders’ equity	$	15,989	$	19,749

Inventories (Tables)

12 Months Ended

Dec. 31, 2019

Inventory Disclosure [Abstract]

Schedule of Inventories

The composition of inventories as of December 31, 2019 and 2018 was as follows:

	December 31, 2019		December 31, 2018
Raw materials	$	2,405	$	1,119
Work in progress		20		6
Finished goods		876		709
Total inventories	$	3,301	$	1,834

Prepaid Expenses and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2019

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

	December 31, 2019		December 31, 2018
Prepaid insurance	$	123	$	328
Other prepaid expenses		358		334
Receivable due from Surface		-		50
Receivable due from Melt		722		-
Deposits and other current assets		105		125
Total prepaid expenses and other current assets	$	1,308	$	837

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Property, plant and equipment at December 31, 2019 and 2018 consisted of the following:

	December 31, 2019			December 31, 2018
Property, plant and equipment, net:
Computer software and hardware	$	1,732		$	1,662
Furniture and equipment		363			397
Lab and pharmacy equipment		3,164			3,184
Leasehold improvements		5,510			5,496
		10,769			10,739
Accumulated depreciation and amortization		(5,394	)		(4,364	)
	$	5,375		$	6,375

Intangible Assets and Goodwill (Tables)

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

The Company’s intangible assets at December 31, 2019 consisted of the following:

	Amortization									Net
	periods			Accumulated						Carrying
	(in years)	Cost		amortization			Impairment			value
Patents	17-19 years	$	1,102	$	(97	)	$	(259	)	$	746
Licenses	20 years		50		(5	)		-			45
Trademarks	Indefinite		340		-			-			340
Customer relationships	3-15 years		3,000		(1,165	)		(630	)		1,205
Trade name	5 years		16		(14	)		(2	)		-
Non-competition clause	3-4 years		294		(274	)		(20	)		-
State pharmacy licenses	25 years		45		(9	)		(35	)		1
		$	4,847	$	(1,564	)	$	(946	)	$	2,337

Schedule of Amortization Expenses for Intangible Assets

Amortization expense for intangible assets for the year ended December 31 was as follows:

	For the Year Ended		For the Year Ended
	December 31, 2019		December 31, 2018
Patents	$	48	$	28
Licenses		5		-
Customer relationships		151		201
Trade name		1		4
Non-competition clause		-		1
State pharmacy licenses		4		2
	$	209	$	235

Schedule of Estimated Future Amortization Expense

Estimated future amortization expense for the Company’s intangible assets at December 31, 2019 is as follows:

Years ending December 31,
2020	$	187
2021		187
2022		187
2023		187
2024		159
Thereafter		1,430
	$	2,337

Schedule of Goodwill

Changes in the carrying value of the Company’s goodwill during the year ended December 31, 2019 were:

Balance at December 31, 2018	$	2,227
Impairment of Park goodwill (see Note 2)		(1,895	)
Balance at December 31, 2019	$	332

Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2019

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses at December 31, 2019 and 2018 consisted of the following:

	December 31, 2019			December 31, 2018
Accounts payable	$	7,409		$	4,966
Other accrued expenses		49			640
Deferred rent		-			388
Accrued interest (see Note 12)		244			256
Accrued exit fee for note payable (see Note 12)		800			800
Total accounts payable and accrued expenses		8,502			7,050
Less: Current portion		(7,702	)		(6,250	)
Non-current total accrued expenses	$	800		$	800

Debt (Tables)

12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

Summary of Future Minimum Payments

At December 31, 2019, future minimum payments under the Company’s note payable were as follows:

	Amount
2020	$	3,703
2021		4,121
2022		3,828
2023		7,573
Total minimum payments		19,225
Less: amount representing interest		(3,975	)
Notes payable, gross		15,250
Less: unamortized discount		(1,259	)
		13,991
Less: current portion, net of unamortized discount		(1,772	)
Note payable, net of current portion and unamortized debt discount	$	12,219

Leases (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Schedule of Future Lease Payment Under Operating Leases

Future lease payments under operating leases as of December 31, 2019 were as follows:

	Operating Leases
2020	$	1,095
2021		978
2022		998
2023		1,023
2024		1,023
Thereafter		4,465
Total minimum lease payments		9,582
Less: amount representing interest payments		(2,615	)
Total operating lease liabilities		6,967
Less: current portion, operating lease liabilities		(629	)
Operating lease liabilities, net of current portion	$	6,338

Schedule of Future Lease Payment Under Finance Lease

Future lease payments under non-cancelable finance leases as of December 31, 2019 were as follows:

	Finance Lease
2020	$	9
2021		9
2022		9
2023		9
2024		1
Total minimum lease payments		37
Less: amount representing interest payments		(4	)
Present value of future minimum lease payments		33
Less: current portion, finance lease obligation		(7	)
Finance lease obligation, net of current portion	$	26

Schedule of Future Minimum Lease Payments Under Operating Lease and Finance Lease

Future minimum lease payments under operating leases and future minimum capital lease payments as of December 31, 2018 were as follows:

	Capital Leases			Operating Leases
2019	$	751		$	797
2020		-			857
2021		-			742
2022		-			320
2023		-			330
Thereafter		-			196
	$	751		$	3,242
Less: Amounts representing interest		(15	)
Less: Amounts representing unamortized discount		(16	)
Total obligation under capital leases		720
Less: Current portion of capital leases		(720	)
Long term capital lease obligation	$	-

Stockholders' Equity and Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Schedule of Stock Option Plan Activity

A summary of stock option activity under the Plan for the year ended December 31, 2019 is as follows:

	Number of shares			Weighted Avg. Exercise Price		Weighted Avg. Remaining Contractual Life		Aggregate Intrinsic Value
Options outstanding - January 1, 2019		2,482,009		$	5.09
Options granted		362,000		$	6.19
Options exercised		(85,051	)	$	3.56
Options cancelled/forfeit		(102,275	)	$	4.67
Options outstanding - December 31, 2019		2,656,683		$	5.31		5.05	$	7,011
Options exercisable		1,603,530		$	4.57		5.72	$	5,552
Options vested and expected to vest		2,558,998		$	5.26		5.10	$	6,911

Schedule of Fair Value Assumptions

The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees:

	2019			2018
Weighted-average fair value of options granted	$	3.72		$	1.42
Expected terms (in years)		5.07 - 7.00			5.77 - 6.11
Expected volatility		64 - 78	%		76 - 126	%
Risk-free interest rate		1.83 – 2.68	%		2.05 – 3.00	%
Dividend yield		-			-

Schedule of Stock Option Outstanding and Exercisable

The following table summarizes information about stock options outstanding and exercisable at December 31, 2019:

			Weighted
			Average		Weighted				Weighted
			Remaining		Average				Average
	Number		Contractual		Exercise		Number		Exercise
Range of Exercise Prices	Outstanding		Life in Years		Price		Exercisable		Price
$1.47 - $2.60		781,940		6.66	$	2.05		619,016	$	2.10
$3.04 - $4.50		458,622		6.09	$	3.96		440,124	$	3.98
$5.49 - $6.36		440,350		7.91	$	6.15		178,619	$	6.08
$6.64 - $8.99		970,741		1.99	$	8.01		360,741	$	8.24
$42.80		5,030		0.62	$	42.80		5,030	$	42.80
$1.47 - $42.80		2,656,683		5.05	$	5.31		1,603,530	$	4.57

Schedule of Restricted Stock Units Activity

A summary of the Company’s RSU activity and related information for the year ended December 31, 2018 is as follows:

	Number of RSUs			Weighted Average Grant Date Fair Value
RSUs unvested - January 1, 2018		1,298,946		$	2.42
RSUs granted		136,360		$	2.20
RSUs vested		(159,626	)	$	3.94
RSUs cancelled/forfeit		-
RSUs unvested at December 31, 2018		1,275,680		$	2.16

A summary of the Company’s RSU activity and related information for the year ended December 31, 2019 is as follows:

	Number of RSUs			Weighted Average Grant Date Fair Value
RSUs unvested - January 1, 2019		1,275,680		$	2.16
RSUs granted		223,860		$	6.43
RSUs vested		(87,610	)	$	3.42
RSUs cancelled/forfeit		-
RSUs unvested at December 31, 2019		1,411,930		$	2.76

Schedule of Stock Based Compensation Granted to Employees Directors Consultants

	For the Year Ended		For the Year Ended
	December 31, 2019		December 31, 2018
Employees – selling, general and administrative	$	1,464	$	2,251
Directors – selling, general and administrative		300		235
Consultants - selling general and administrative		259		150
Total	$	2,023	$	2,636

Schedule of Warrants Activity

A summary of warrant activity during the year ended December 31, 2019 is as follows:

	Number of Shares Subject to Warrants Outstanding			Weighted Avg. Exercise Price

Warrants outstanding - January 1, 2019		2,206,973		$	1.91
Granted		-
Exercised		(1,418,587	)	$	1.79
Expired		(8,000	)	$	1.79
Warrants outstanding and exercisable - December 31, 2019		780,386		$	2.12
Weighted average remaining contractual life of the outstanding warrants in years - December 31, 2019		4.53

Schedule of Warrants Outstanding and Warrants Exercisable

All warrants outstanding as of December 31, 2019 are included in the following table:

	Warrants Outstanding					Warrants Exercisable
		Warrants		Exercise		Warrants		Expiration
Warrant Series	Issue Date	Outstanding		Price		Exercisable		Date
Lender warrants	5/11/2015		125,000	$	1.79		125,000		5/11/2025
Settlement warrants	8/16/2016		40,000	$	3.75		40,000		8/16/2021
Lender warrants (see Note 12)	7/19/2017		615,386	$	2.08		615,386		7/19/2024
			780,386	$	2.12		780,386

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Schedule of Provision for Income Taxes

	December 31, 2019			December 31, 2018
Current:
Federal	$	-		$	-
State		8			6
Total current	$	8		$	6

Deferred:
Federal	$	669		$	3,294
State		(148	)		440
Change in valuation allowance		(521	)		(3,734	)
Total deferred		0			0
Income tax provision (benefit)	$	8		$	6

Schedule of Income Tax Reconciliation

A reconciliation of income taxes computed by applying the statutory U.S. income tax rate to the Company’s loss before income taxes to the income tax provision is as follows:

	December 31, 2019			December 31, 2018
U.S. federal statutory tax rate		21.00	%		21.00	%
Benefit of lower tax brackets		0.00	%		0.00	%
State tax benefit, net		(6.73	)%		0.04	%
Research and development credits		0.00	%		(0.14	)%
Employee stock-based compensation		3.10	%		0.46	%
Loss on debt conversion		0.00	%		0.00	%
Capitalization of Subsidiary		0.00	%		0.00	%
Change in Rate		0.00	%		0.00	%
Other		(358.67	)%		0.13	%
Valuation allowance		334.57	%		(21.93	)%
Effective income tax rate		(6.73	)%		(0.44	)%

Schedule of Deferred Tax Assets and Liabilities

	December 31, 2019			December 31, 2018
Deferred tax assets (liabilities):
NOLs	$	19,827		$	19,726
Depreciation and amortization		224			30
Other		640			604
Research and development credits		596			617
Deferred stock compensation		3,533			3,036
Basis Difference in Melt		(1,185	)		-
Basis Difference in Surface		(1,119	)		(1,464	)
Basis Difference in Eton		(7,528	)		(6,340	)
Capital Losses		62			-
Park stock purchase identifiable intangibles		(270	)		(484	)
Limitation Under 163(j)		299			-
ASC 842 Lease Liability		2,082			-
ASC 842 ROU Asset		(1,959	)		-
Total deferred tax assets, net		15,202			15,723
Valuation allowance		(15,202	)		(15,723	)
Net deferred tax liabilities	$	-		$	-

Schedule of Change in Unrecognized Tax Benefits

A reconciliation of the change in the UTB balance from January 1, 2019 to December 31, 2019 is as follows:

	Fed & State Tax
Balance at January 1, 2019	$	-
Additions for tax positions related to current year		-
Additions/(reductions) for tax positions related to prior years		-

Balance at December 31, 2019		-

Total unrecognized tax benefits as of December 31, 2019		-

Segment Information and Concentrations (Tables)

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Schedule of Segment Net Revenues, Segment Operating Expenses and Segment Contribution

Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the year ended December 31, 2019:

	For the Year Ended December 31, 2019
	Pharmaceutical			Pharmaceutical
	Compounding			Drug Development			Total
Net revenues	$	51,165		$	-		$	51,165
Cost of sales		(16,749	)		-			(16,749	)
Gross profit		34,416			-			34,416

Operating expenses:
Selling, general and administrative		24,468			174			24,642
Research and development		1,006			361			1,367
Segment contribution	$	8,942		$	(535	)	$	8,407
Corporate								8,245
Research and development								716
Amortization								209
Asset sales and impairments, net								4,040
Operating loss							$	(4,803	)

Summary of Significant Accounting Policies (Details Narrative) $ / shares in Units, $ in Thousands		1 Months Ended						12 Months Ended
	Mar. 03, 2019 USD ($)	Jan. 31, 2019 USD ($) $ / shares	Nov. 30, 2018 USD ($) $ / shares shares	Jul. 31, 2018 USD ($) $ / shares	May 31, 2018 USD ($) $ / shares	Jan. 31, 2018 USD ($)	Jun. 30, 2017 USD ($)	Dec. 31, 2019 USD ($) Segment $ / shares shares	Dec. 31, 2018 USD ($) shares	Mar. 31, 2019 $ / shares
Consolidation basis, description								We consolidate subsidiaries in which we hold and/or control, directly or indirectly, more than 50% of the voting rights.
Cash resources and restricted investments, marketable securities								$ 30,149
Number of segments \| Segment								2
Non-controlling interest description								Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors, such as decision-making rights, that are considered as well.
FDIC insured amount								$ 250
Accounts receivable, net of allowance for doubtful accounts								$ 76	$ 270
Intangible assets estimated useful life								20 years
Right of use asset								$ 6,559
Operating and finance leases								$ 6,967
Restricted Stock Units [Member]
Number of shares issued \| shares									99,626
Number of shares vested during the period \| shares								324,303	236,693
Stock Options, Unvested RSUs and Warrants [Member]
Antidilutive securities \| shares								4,848,459	6,201,355
Minimum [Member]
Property and equipment estimated useful life								3 years
Maximum [Member]
Property and equipment estimated useful life								5 years
Eton Pharmaceuticals, Inc. [Member]
Ownership percentage			19.98%
Gain on deconsolidation amount							$ 5,725
Net loss on equity								$ 0	$ 3,507
Stock price per shares \| $ / shares								$ 7.20
Gain (loss) on investment								$ 3,780	21,420
Fair market value of investments								25,200
Payment to acquire patent rights				$ 50
Eton Pharmaceuticals, Inc. [Member] \| Licensing Agreement [Member]
Milestone payments received						$ 50		$ 50
Royalty fee, percentage								0.06
Eton Pharmaceuticals, Inc. [Member] \| IPO [Member]
Number of shares issued \| shares			4,140,000
Stock price per shares \| $ / shares			$ 6.00
Stock issued during period value			$ 24,800
Melt Pharmaceuticals, Inc. [Member]
Ownership percentage								44.00%
Gain on deconsolidation amount								$ 5,810
Net loss on equity								$ 1,842
Number of shares owned \| shares								3,500,000
Carrying value of investments								$ 3,968
Melt Pharmaceuticals, Inc. [Member] \| Series A Preferred Stock [Member]
Stock price per shares \| $ / shares		$ 5.00								$ 5.00
Proceeds from issuance of preferred stock	$ 11,400	$ 11,400
Surface Pharmaceuticals, Inc [Member]
Ownership percentage								30.00%
Gain on deconsolidation amount								$ 5,320
Net loss on equity								$ 1,200	$ 373
Number of shares owned \| shares								3,500,000
Carrying value of investments								$ 3,747
Surface Pharmaceuticals, Inc [Member] \| Series A Preferred Stock [Member]
Stock price per shares \| $ / shares				$ 3.30	$ 3.30
Proceeds from issuance of preferred stock				$ 21,000	$ 21,000
Park Compounding, Inc. and Noice Rx, LLC [Member]
Non-cash impairment costs								3,781
Severance packages and other costs								$ 480
Mayfield Pharmaceuticals, Inc. [Member]
Ownership percentage								70.00%
Mayfield Pharmaceuticals, Inc. [Member] \| Elle Pharmaceutical, LLC [Member]
Ownership percentage								30.00%
Mayfield Pharmaceuticals, Inc. [Member] \| TGV-Health, LLC [Member]
Ownership percentage								30.00%
Stowe Pharmaceuticals, Inc. [Member]
Ownership percentage								70.00%
Stowe Pharmaceuticals, Inc. [Member] \| TGV-Health, LLC [Member]
Ownership percentage								30.00%

Summary of Significant Accounting Policies - Schedule of Basic Earnings Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Numerator - net income	$ 168	$ 14,625
Denominator - weighted average number of shares outstanding, basic	25,323,159	21,917,570
Net income per share, basic	$ 0.01	$ 0.67

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Summary of Significant Accounting Policies - Schedule of Diluted Common Equivalent Shares (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Dilutive common equivalent shares	26,466,098	23,812,045
Stock Options [Member]
Dilutive common equivalent shares	654,441	50,203
Warrants [Member]
Dilutive common equivalent shares	488,498	1,844,272
Common Stock [Member]
Dilutive common equivalent shares	25,323,159	21,917,570

Summary of Significant Accounting Policies - Schedule of Diluted Earnings Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Numerator - net income	$ 168	$ 14,625
Weighted average number of shares outstanding, basic	25,323,159	21,917,570
Dilutive common equivalents	1,142,939	1,894,475
Denominator - number of shares used for diluted earnings per share computation	26,466,098	23,812,045
Net income per share, diluted	$ 0.01	$ 0.61

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Revenues (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Deferred revenue and customer deposits	$ 57	$ 119

Revenues - Schedule of Disaggregated Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Total Revenues	$ 51,165	$ 41,372
Product Sales, Net [Member]
Total Revenues	51,137	41,334
License Revenues [Member]
Total Revenues	$ 28	$ 38

Investment in Melt Pharmaceuticals, Inc. and Agreements - Related Party Transactions (Details Narrative) - Melt Pharmaceuticals, Inc. [Member] - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Feb. 28, 2019	Dec. 31, 2018	Dec. 31, 2019
Asset Purchase Agreement [Member]
Royalty payment percentage on net sales		5.00%
Management Services Agreement [Member]
Administrative expenses	$ 10
Reimbursable expenses due			$ 722
Proceeds from related party payments			$ 50

Investment in Melt Pharmaceuticals, Inc. and Agreements - Related Party Transactions - Schedule of Condensed Income Statement (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues, net	$ 51,165	$ 41,372
Loss from operations	(4,803)	(5,217)
Net loss	168	$ 14,625
Melt Pharmaceuticals, Inc. [Member]
Revenues, net
Loss from operations	4,169
Net loss	$ (4,169)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Investment in Melt Pharmaceuticals, Inc. and Agreements - Related Party Transactions - Schedule of Condensed Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets	$ 36,767	$ 32,843
Total assets	59,085	49,451
Total liabilities	31,667	24,700
Total preferred stock and stockholders' equity	27,711	24,751
Total liabilities and stockholders' equity	59,085	$ 49,451
Melt Pharmaceuticals, Inc. [Member]
Current assets	7,440
Non current assets	13
Total assets	7,453
Total liabilities	1,656
Total preferred stock and stockholders' equity	5,797
Total liabilities and stockholders' equity	$ 7,453

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(11))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(12))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(16))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(10))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Investment in Surface Pharmaceuticals, Inc. and Agreements - Related Party Transactions (Details Narrative) - Surface Pharmaceuticals, Inc [Member] - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2018	Dec. 31, 2019
Number of shares owned		3,500,000
Ownership percentage		30.00%
Dr. Lindstrom [Member]
Royalty payment percentage on net sales		3.00%
Two Asset Purchase and License Agreement [Member] \| Minimum [Member]
Royalty payment percentage on net sales		4.00%
Two Asset Purchase and License Agreement [Member] \| Maximum [Member]
Royalty payment percentage on net sales		6.00%
Management Services Agreement [Member]
Administrative expenses	$ 10
Proceeds from related party payments		$ 50
Reimbursable expenses due

Investment in Surface Pharmaceuticals, Inc. and Agreements - Related Party Transactions - Schedule of Condensed Income Statement (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues, net	$ 51,165	$ 41,372
Loss from operations	(4,803)	(5,217)
Net loss	168	14,625
Surface Pharmaceuticals, Inc [Member]
Revenues, net
Loss from operations	4,000	1,370
Net loss	$ (4,000)	$ (1,370)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Investment in Surface Pharmaceuticals, Inc. and Agreements - Related Party Transactions - Schedule of Condensed Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets	$ 36,767	$ 32,843
Total assets	59,085	49,451
Total liabilities	31,667	24,700
Total stockholders equity	27,711	24,751
Total liabilities and stockholders' equity	59,085	49,451
Surface Pharmaceuticals, Inc [Member]
Current assets	15,942	19,699
Non current assets	47	50
Total assets	15,989	19,749
Total liabilities	619	165
Total stockholders equity	15,370	19,584
Total liabilities and stockholders' equity	$ 15,989	$ 19,749

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.

+ References

+ Details

Restricted Cash (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Restricted Cash [Abstract]
Restricted cash	$ 200	$ 200

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 2,405	$ 1,119
Work in progress	20	6
Finished goods	876	709
Total inventories	$ 3,301	$ 1,834

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Prepaid insurance	$ 123	$ 328
Other prepaid expenses	358	334
Deposits and other current assets	105	125
Total prepaid expenses and other current assets	1,308	837
Surface Pharmaceuticals, Inc [Member]
Receivable due from related party		50
Melt Pharmaceuticals, Inc. [Member]
Receivable due from related party	$ 722

Property, Plant and Equipment (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation and amortization of property, plant and equipment	$ 1,936	$ 1,608

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Computer software and hardware	$ 1,732	$ 1,662
Furniture and equipment	363	397
Lab and pharmacy equipment	3,164	3,184
Leasehold improvements	5,510	5,496
Property, plant and equipment, gross	10,769	10,739
Accumulated depreciation and amortization	(5,394)	(4,364)
Property, plant and equipment, Net	$ 5,375	$ 6,375

Intangible Assets and Goodwill (Details Narrative) - Park Compounding, Inc. [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Customer Relationships, Trade Name and State Pharmacy Licenses [Member]
Impairment of intangible assets	$ 612
Patents [Member]
Impairment of intangible assets	$ 259

Intangible Assets and Goodwill - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Amortization periods (in years)	20 years
Cost	$ 4,847
Accumulated amortization	(1,564)
Impairment	(946)
Net Carrying value	2,337	$ 3,059
Patents [Member]
Cost	1,102
Accumulated amortization	(97)
Impairment	(259)
Net Carrying value	$ 746
Patents [Member] \| Minimum [Member]
Amortization periods (in years)	17 years
Patents [Member] \| Maximum [Member]
Amortization periods (in years)	19 years
Licenses [Member]
Amortization periods (in years)	20 years
Cost	$ 50
Accumulated amortization	(5)
Impairment
Net Carrying value	$ 45
Trademarks [Member]
Amortization periods description	Indefinite
Cost	$ 340
Accumulated amortization
Impairment
Net Carrying value	340
Customer Relationships [Member]
Cost	3,000
Accumulated amortization	(1,165)
Impairment	(630)
Net Carrying value	$ 1,205
Customer Relationships [Member] \| Minimum [Member]
Amortization periods (in years)	3 years
Customer Relationships [Member] \| Maximum [Member]
Amortization periods (in years)	15 years
Trade Name [Member]
Amortization periods (in years)	5 years
Cost	$ 16
Accumulated amortization	(14)
Impairment	(2)
Net Carrying value
Non-Competition Clause [Member]
Cost	294
Accumulated amortization	(274)
Impairment	(20)
Net Carrying value
Non-Competition Clause [Member] \| Minimum [Member]
Amortization periods (in years)	3 years
Non-Competition Clause [Member] \| Maximum [Member]
Amortization periods (in years)	4 years
State Pharmacy Licenses [Member]
Amortization periods (in years)	25 years
Cost	$ 45
Accumulated amortization	(9)
Impairment	(35)
Net Carrying value	$ 1

Intangible Assets and Goodwill - Schedule of Amortization Expenses for Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Amortization of intangible assets	$ 209	$ 235
Patents [Member]
Amortization of intangible assets	48	28
Licenses [Member]
Amortization of intangible assets	5
Customer Relationships [Member]
Amortization of intangible assets	151	201
Trade Name [Member]
Amortization of intangible assets	1	4
Non-Competition Clause [Member]
Amortization of intangible assets		1
State Pharmacy Licenses [Member]
Amortization of intangible assets	$ 4	$ 2

Intangible Assets and Goodwill - Schedule of Estimated Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2019 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 187
2021	187
2022	187
2023	187
2024	159
Thereafter	1,430
Intangible assets	$ 2,337

Intangible Assets and Goodwill - Schedule of Goodwill (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning balance	$ 2,227
Impairment of Park goodwill	(1,895)
Ending balance	$ 332

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accounts payable	$ 7,409	$ 4,966
Other accrued expenses	49	640
Deferred rent		388
Accrued interest	244	256
Accrued exit fee for note payable	800	800
Total accounts payable and accrued expenses	8,502	7,050
Less: Current portion	(7,702)	(6,250)
Non-current total accrued expenses	$ 800	$ 800

Debt (Details Narrative) $ / shares in Units, $ in Thousands		1 Months Ended		12 Months Ended
	Apr. 30, 2019 USD ($)	May 31, 2019 USD ($)	Apr. 30, 2019 USD ($)	Dec. 31, 2019 USD ($) $ / shares	Dec. 31, 2018 USD ($)	Aug. 31, 2017 $ / shares shares	Jul. 31, 2017 USD ($) $ / shares shares
Liability of final fee included in accrued expenses				$ 800	$ 800
Fair value warrant adjustments				982
Amortization of debt discount				17
Notes Payable [Member]
Amortization of debt discount				$ 495	$ 520
Warrants [Member]
Warrant exercise price per share \| $ / shares				$ 2.12
Expected Term [Member] \| Warrants [Member]
Warrant term						7 years
Volatility [Member] \| Warrants [Member]
Fair value assumptions, measurement input, percentages						113.5
Dividend Rate [Member] \| Warrants [Member]
Fair value assumptions, measurement input, percentages						0
Risk Free Interest Rate [Member] \| Warrants [Member]
Fair value assumptions, measurement input, percentages						1.77
Lender Warrants [Member]
Warrant to purchase of common stock \| shares							415,586
Warrant exercise price per share \| $ / shares							$ 3.08
Warrant term							7 years
SWK Warrants [Member]
Warrant to purchase of common stock \| shares						615,386
Warrant exercise price per share \| $ / shares						$ 2.08
Fair value assumptions, measurement input, per share \| shares						2.08
London Inter-Bank Offered Rate [Member]
Loan bear interest at variable rate			10.50%
Loan bear interest at variable rate, description			Prior to the loan refinance in May 2019 (see below), the SWK Loan was bearing interest at a variable rate equal to the three-month London Inter-Bank Offered Rate (subject to a minimum of 1.50% and maximum of 3.00%), plus an applicable margin of 10.50%.
London Inter-Bank Offered Rate [Member] \| Minimum [Member]
Loan bear interest at variable rate			1.50%
London Inter-Bank Offered Rate [Member] \| Maximum [Member]
Loan bear interest at variable rate			3.00%
Term Loan and Security Agreement [Member] \| SWK Funding LLC [Member]
Debt principal amount							$ 16,000
SWK Loan Agreement [Member]
Repayment of debt	$ 750
Debt due date description	All amounts owed under the SWK Loan Agreement, including a final fee equal to 5% of the aggregate principal amount loaned thereunder, were previously due and payable on July 19, 2022.
Incurred expense debt	$ 1,282		$ 1,282
Joinder and Amendment [Member]
Debt principal amount		$ 5,000
Loan bear interest at variable rate, description		The interest rate calculation that the loan bears is now equal to the three-month London Inter-Bank Offered Rate (subject to a minimum of 2.00%), plus an applicable margin of 10.00% (the "Margin Rate"); provided that, if, two days prior to a payment date, the Company provides the SWK evidence that the Company has achieved a leverage ratio as of such date of less than 4.00:1:00, the Margin Rate shall equal 9.00%; and if the Company has achieved a leverage ratio as of such date of less than 3.00:1:00, the Margin Rate shall equal 7.00%
Deconsolidation percentage		50.00%
Legal and lender costs		$ 282
Joinder and Amendment [Member] \| London Inter-Bank Offered Rate [Member] \| Minimum [Member]
Loan bear interest at variable rate		2.00%
Joinder and Amendment [Member] \| Margin Rate [Member]
Loan bear interest at variable rate		10.00%

Debt - Summary of Future Minimum Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Less: current portion, net of unamortized discount	$ (1,772)	$ (2,529)
Note payable, net of current portion and unamortized debt discount	12,219	$ 11,999
Note Payable [Member]
2020	3,703
2021	4,121
2022	3,828
2023	7,573
Total minimum payments	19,225
Less: amount representing interest	(3,975)
Notes payable, gross	15,250
Less: unamortized discount	(1,259)
Notes payable	13,991
Less: current portion, net of unamortized discount	(1,772)
Note payable, net of current portion and unamortized debt discount	$ 12,219

Leases (Details Narrative) $ in Thousands		1 Months Ended	12 Months Ended
Leases (Details Narrative) $ in Thousands	Jan. 02, 2019 USD ($)	Oct. 31, 2019 USD ($) ft²	Dec. 31, 2019 USD ($) ft²	Dec. 31, 2018 USD ($)
Lease term description			The Company has elected to not recognize right-of-use assets and lease liabilities arising from short-term leases, which are leases that, at the commencement date, have a lease term of 12 months or less and do not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise.
Weighted average incremental borrowing rate, operating lease			6.30%
Weighted average remaining lease term, operating lease			10 years 2 months 16 days
Decrease in accounts payable and accrued expenses			$ 1,342	$ 2,365
Operating lease right use of assets			6,559
Operating lease liability			6,967
Cash paid in operating lease liability			905
Operating lease expense			$ 892
Weighted average incremental borrowing rate, finance lease			6.36%
Weighted average remaining lease term, finance lease			4 years 29 days
Debt discount amortization			$ 17
Depreciation expenses			150
Cash paid for interest expenses			$ 18
Nashville [Member]
Operating lease space \| ft²		5,500
Increase in operating lease right-of-use assets		$ 753
Increase in operating lease liability		$ 753
ASU- 2016-02 [Member]
Increase in operating lease right-of-use assets	$ 6,325
Decrease in accounts payable and accrued expenses	388
Increase in operating lease liability	$ 6,712
ASU- 2016-02 [Member] \| San Diego [Member]
Operating lease space \| ft²			10,200
Operating lease expires date			Dec. 31, 2021
Lease term			5 years
Lease term description			Term for a five-year period
ASU- 2016-02 [Member] \| Irvine [Member]
Operating lease space \| ft²			4,500
Operating lease expires date			Dec. 31, 2020
Lease term description			Term for up to two five-year periods
ASU- 2016-02 [Member] \| Ledgewood [Member]
Operating lease space \| ft²			25,000
Operating lease expires date			Jul. 31, 2024
Lease term description			Term for two additional five-year periods.
ASU- 2016-02 [Member] \| Nashville [Member]
Operating lease space \| ft²			5,500
Operating lease expires date			Dec. 31, 2024
Lease term description			Term for two additional five-year periods.

Leases - Schedule of Future Lease Payment Under Operating Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
2020	$ 1,095
2021	978
2022	998
2023	1,023
2024	1,023
Thereafter	4,465
Total minimum lease payments	9,582
Less: amount representing interest payments	(2,615)
Total operating lease liabilities	6,967
Less: current portion, operating lease liabilities	(629)
Operating lease liabilities, net of current portion	$ 6,338

Leases - Schedule of Future Lease Payment Under Finance Lease (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
2020	$ 9
2021	9
2022	9
2023	9
2024	1
Total minimum lease payments	37
Less: amount representing interest payments	(4)
Present value of future minimum lease payments	33
Less: current portion, finance lease obligation	(7)	$ (720)
Finance lease obligation, net of current portion	$ 26

Leases - Schedule of Future Minimum Lease Payments Under Operating Lease and Finance Lease (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
2020	$ 9
2021	9
2022	9
2023	1
Financing lease payment	37
Less: Amounts representing unamortized discount	(4)
Total obligation under capital leases	33
Less: Current portion of capital leases	(7)	$ (720)
Long term capital lease obligation	26
2019	1,095
2020	978
2021	998
2022	1,023
2023	1,023
Thereafter	4,465
Operating lease payment	$ 9,582
Capital Lease [Member]
2019		751
2020
2021
2022
2023
Thereafter
Financing lease payment		751
Less: Amounts representing interest		(15)
Less: Amounts representing unamortized discount		(16)
Total obligation under capital leases		720
Less: Current portion of capital leases		(720)
Long term capital lease obligation
Operating Lease [Member]
2019		797
2020		857
2021		742
2022		320
2023		330
Thereafter		196
Operating lease payment		$ 3,242

Stockholders' Equity and Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended						12 Months Ended
	Feb. 28, 2018	Jul. 31, 2019	Mar. 31, 2019	Feb. 28, 2019	Dec. 31, 2018	Mar. 31, 2018	Jan. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jul. 10, 2018
Common stock, shares authorized					50,000,000			50,000,000	50,000,000
Common stock, par value					$ 0.001			$ 0.001	$ 0.001
Shares issued of restricted common stock, shares			15,000		15,000	35,427	25,273
Accrued royalty expense						$ 64	$ 44	$ 846	$ 561
Fair value of restricted common stock issued			$ 75		$ 42
Options exercise price, minimum								$ 1.47
Options exercise price, maximum								$ 42.80
Proceeds from issuance of common stock									$ 642
Preferred stock, shares authorized					5,000,000			5,000,000	5,000,000
Preferred stock, par value					$ 0.001			$ 0.001	$ 0.001
Preferred stock, shares issued
Preferred stock, shares outstanding
Stock-based compensation								$ 1,789	$ 2,486
Mayfield Pharmaceuticals, Inc. [Member] \| Elle Pharmaceutical, LLC [Member]
Number of shares issued for acquisition				1,000,000
Mayfield Pharmaceuticals, Inc. [Member] \| TGV-Gyneconix, LLC [Member]
Shares issued of restricted common stock, shares		300,000
Stowe Pharmaceuticals, Inc. [Member] \| TGV-Ophthalnix, LLC [Member]
Shares issued of restricted common stock, shares		1,750,000
2017 Incentive Stock and Awards Plan [Member]
Maximum number of common stock issuance under the plan								2,000,000
Shares available for future issuances								1,004,656
Exercise Price $1.70 to $4.17 [Member]
Options exercise price, minimum								$ 1.47
Options exercise price, maximum								2.60
Exercise Price $1.70 to $3.20 [Member]
Options exercise price, minimum								3.04
Options exercise price, maximum								$ 4.50
Consultants, Employees and Directors [Member]
Stock-based compensation									$ 21
Mark Baum, CEO [Member] \| Mayfield Pharmaceuticals, Inc. [Member]
Number of common stock issued for consultants services								725,000
Andrew Boll, CFO [Member] \| Mayfield Pharmaceuticals, Inc. [Member]
Number of common stock issued for consultants services								362,500
Restricted Stock Units [Member]
Shares issued of restricted common stock, shares								185,000
Fair value of restricted common stock issued								$ 1,139
Number of shares issued									99,626
Restricted Stock Units [Member] \| Andrew R. Boll [Member]
Shares issued of restricted common stock, shares	30,000
Restricted Stock Units [Member] \| John P. Saharek [Member]
Shares issued of restricted common stock, shares	30,000
Restricted Stock Units [Member] \| Directors [Member]
Number of shares issued								87,610
Restricted Stock Units [Member] \| Non Employee Directors [Member]
Shares issued of restricted common stock, shares									136,360
Fair value of restricted common stock issued									$ 300
Restricted Stock Units [Member] \| Board of Directors [Member]
Shares issued of restricted common stock, shares								38,860
Fair value of restricted common stock issued								$ 300
Stock Option [Member]
Common stock withheld for payroll tax withholdings								8,806
Common stock withheld for payroll tax withholdings, value								$ 50
Stock Option [Member] \| Exercise Price $1.70 to $4.17 [Member]
Number of shares issued								27,671
Number of options exercised								82,929
Options exercise price, minimum								$ 1.70
Options exercise price, maximum								$ 4.17
Stock Option [Member] \| Exercise Price $1.70 to $3.20 [Member]
Number of shares issued								2,122
Number of options exercised								2,122
Options exercise price, minimum								$ 1.70
Options exercise price, maximum								$ 3.20
Proceeds from issuance of common stock								$ 6
Stock Option Plan [Member]
Closing price of common stock price per share								$ 7.78
Intrinsic value of options exercised								$ 246
Forfeiture factor, percentage								10.00%
Unrecognized compensation expense related to unvested stock options granted under the plan								$ 3,848
Expense expected to recognize over the weighted-average remaining vesting period								1 year 4 months 13 days
Stock-based compensation								$ 889	1,317
Stock Option Plan [Member] \| Employees and Consultant [Member] \| Minimum [Member]
Stock options granted with exercise price contractual terms								5 years
Stock Option Plan [Member] \| Employees and Consultant [Member] \| Maximum [Member]
Stock options granted with exercise price contractual terms								10 years
Stock options granted vesting terms								Vesting terms for options granted in 2019 and 2018 to employees and consultants typically included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; quarterly vesting over three years; and 90% of the shares subject to the option vest and become exercisable on the second month after the grant date and the remaining 10% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over the next 11 months. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plan) and in the event of certain modifications to the option award agreement.
Unvested RSUs [Member]
Unrecognized compensation expense related to unvested stock options granted under the plan								$ 1,031
Expense expected to recognize over the weighted-average remaining vesting period								3 months 19 days
Stock-based compensation								$ 879	$ 1,149
Restricted Stock [Member] \| Mayfield Pharmaceuticals, Inc. [Member]
Shares issued of restricted common stock, shares								2,450,000
Stock-based compensation								$ 26
Common Stock Warrants [Member]
Number of shares issued									2,364,889
Warrants exercise price					$ 1.79				$ 1.79
Proceeds from issuance of warrant									$ 4,233
Common Stock Warrant One [Member]
Number of shares issued									910,273
Warrants exercise price					$ 1.79				$ 1.79
Number of warrants exercised					1,576,665				1,576,665
Common Stock Warrants One [Member]
Number of shares issued								688,473
Warrants exercise price								$ 1.79
Number of warrants exercised								964,532
Common Stock Warrants Two [Member]
Number of shares issued								454,055
Warrants exercise price								$ 1.79
Proceeds from issuance of warrant								$ 813
Number of warrants exercised								454,055
Amended and Restated Certificate of Incorporation [Member] \| Previously Authorized Shares [Member]
Common stock, shares authorized										90,000,000
Sales Agreement [Member]
Number of shares sold under the agreement									305,619
Proceeds from sale of common stock approximately									$ 642
Sales commission and offering expenses									$ 20

Stockholders' Equity and Stock-Based Compensation - Schedule of Stock Option Plan Activity (Details) - Stock Option Plan [Member] $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($) $ / shares shares
Number of shares, Outstanding, Beginning balance \| shares	2,482,009
Number of shares, Options granted \| shares	362,000
Number of shares, Options exercised \| shares	(85,051)
Number of shares, Options cancelled/forfeited \| shares	(102,275)
Number of shares, Outstanding, Ending balance \| shares	2,656,683
Number of shares, Options exercisable \| shares	1,603,530
Number of shares, Options vested and expected to vest \| shares	2,558,998
Weighted Avg. Exercise Price, Outstanding, Beginning balance \| $ / shares	$ 5.09
Weighted Avg. Exercise Price, Options granted \| $ / shares	6.19
Weighted Avg. Exercise Price, Options exercised \| $ / shares	3.56
Weighted Avg. Exercise Price, Options cancelled/forfeited \| $ / shares	4.67
Weighted Avg. Exercise Price, Outstanding, Ending balance \| $ / shares	5.31
Weighted Avg. Exercise Price, Exercisable Ending Balance \| $ / shares	4.57
Weighted Avg. Exercise Price, Vested and expected to vest \| $ / shares	$ 5.26
Weighted Avg. Remaining Contractual Life, Options outstanding	5 years 18 days
Weighted Avg. Remaining Contractual Life, Options exercisable	5 years 8 months 19 days
Weighted Avg. Remaining Contractual Life, Options vested and expected to vest	5 years 1 month 6 days
Aggregate Intrinsic Value, Options outstanding \| $	$ 7,011
Aggregate Intrinsic Value, Options exercisable \| $	5,552
Aggregate Intrinsic Value, Options vested and expected to vest \| $	$ 6,911

Stockholders' Equity and Stock-Based Compensation - Schedule of Fair Value Assumptions (Details) - Options Granted to Employees [Member] - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Weighted-average fair value of options granted	$ 3.72	$ 1.42
Expected volatility, minimum	64.00%	76.00%
Expected volatility, maximum	78.00%	126.00%
Risk-free interest rate, minimum	1.83%	2.05%
Risk-free interest rate, maximum	2.68%	3.00%
Dividend yield	0.00%	0.00%
Minimum [Member]
Expected terms (in years)	5 years 26 days	5 years 9 months 7 days
Maximum [Member]
Expected terms (in years)	7 years	6 years 1 month 9 days

Stockholders' Equity and Stock-Based Compensation - Schedule of Stock Option Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2019 $ / shares shares
Range of Exercise Prices, minimum	$ 1.47
Range of Exercise Prices, maximum	$ 42.80
Number of Options Outstanding \| shares	2,656,683
Weighted Average Remaining Contractual Life in Years	5 years 18 days
Weighted Average Exercise Price	$ 5.31
Number Exercisable \| shares	1,603,530
Weighted Average Exercisable Exercise Price	$ 4.57
Range One [Member]
Range of Exercise Prices, minimum	1.47
Range of Exercise Prices, maximum	$ 2.60
Number of Options Outstanding \| shares	781,940
Weighted Average Remaining Contractual Life in Years	6 years 7 months 28 days
Weighted Average Exercise Price	$ 2.05
Number Exercisable \| shares	619,016
Weighted Average Exercisable Exercise Price	$ 2.10
Range Two [Member]
Range of Exercise Prices, minimum	3.04
Range of Exercise Prices, maximum	$ 4.50
Number of Options Outstanding \| shares	458,622
Weighted Average Remaining Contractual Life in Years	6 years 1 month 2 days
Weighted Average Exercise Price	$ 3.96
Number Exercisable \| shares	440,124
Weighted Average Exercisable Exercise Price	$ 3.98
Range Three [Member]
Range of Exercise Prices, minimum	5.49
Range of Exercise Prices, maximum	$ 6.36
Number of Options Outstanding \| shares	440,350
Weighted Average Remaining Contractual Life in Years	7 years 10 months 28 days
Weighted Average Exercise Price	$ 6.15
Number Exercisable \| shares	178,619
Weighted Average Exercisable Exercise Price	$ 6.08
Range Four [Member]
Range of Exercise Prices, minimum	6.64
Range of Exercise Prices, maximum	$ 8.99
Number of Options Outstanding \| shares	970,741
Weighted Average Remaining Contractual Life in Years	1 year 11 months 26 days
Weighted Average Exercise Price	$ 8.01
Number Exercisable \| shares	360,741
Weighted Average Exercisable Exercise Price	$ 8.24
Range Five [Member]
Range of Exercise Prices, maximum	$ 42.80
Number of Options Outstanding \| shares	5,030
Weighted Average Remaining Contractual Life in Years	7 months 13 days
Weighted Average Exercise Price	$ 42.80
Number Exercisable \| shares	5,030
Weighted Average Exercisable Exercise Price	$ 42.80

Stockholders' Equity and Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Number of RSUs unvested, Outstanding, Beginning balance	1,275,680	1,298,946
Number of RSUs granted	223,860	136,360
Number of RSUs vested	(87,610)	(159,626)
Number of RSUs cancelled/forfeit
Number of RSUs unvested, Outstanding, Ending balance	1,411,930	1,275,680
Weighted Average Grant Date Fair Value, Beginning balance	$ 2.16	$ 2.42
Weighted Average Grant Date Fair Value, RSUs granted	6.43	2.20
Weighted Average Grant Date Fair Value, RSUs vested	3.42	3.94
Weighted Average Grant Date Fair Value, Ending balance	$ 2.76	$ 2.16

Stockholders' Equity and Stock-based Compensation - Schedule of Stock Based Compensation Granted to Employees Directors Consultants (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Stock based compensation related to equity instruments granted to related parties	$ 2,023	$ 2,636
Employees [Member] \| Selling, General and Administrative [Member]
Stock based compensation related to equity instruments granted to related parties	1,464	2,251
Directors [Member] \| Selling, General and Administrative [Member]
Stock based compensation related to equity instruments granted to related parties	300	235
Consultants [Member] \| Selling, General and Administrative [Member]
Stock based compensation related to equity instruments granted to related parties	$ 259	$ 150

Stockholders' Equity and Stock-based Compensation - Schedule of Warrants Activity (Details) - Warrants [Member]	12 Months Ended
	Dec. 31, 2019 $ / shares shares
Number of Shares Warrants Outstanding, beginning balance	2,206,973
Number of Shares Warrants Outstanding, Granted
Number of Shares Warrants Outstanding, Exercised	(1,418,587)
Number of Shares Warrants Outstanding, Expired	(8,000)
Number of Shares Warrants Outstanding and Exercisable, ending balance	780,386
Weighted average remaining contractual life of the outstanding warrants in years	4 years 6 months 10 days
Weighted Avg. Exercise Price, Outstanding, beginning balance \| $ / shares	$ 1.91
Weighted Avg. Exercise Price, Exercised \| $ / shares	1.79
Weighted Avg. Exercise Price, Expired \| $ / shares	1.79
Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance \| $ / shares	$ 2.12

Stockholders' Equity and Stock-based Compensation - Schedule of Warrants Outstanding and Warrants Exercisable (Details)	12 Months Ended
	Dec. 31, 2019 $ / shares shares
Warrants [Member]
Warrants Outstanding	780,386
Exercise Price \| $ / shares	$ 2.12
Warrants Exercisable	780,386
Lender Warrants [Member]
Issue Date	May 11, 2015
Warrants Outstanding	125,000
Exercise Price \| $ / shares	$ 1.79
Warrants Exercisable	125,000
Expiration Date	May 11, 2025
Settlement Warrants [Member]
Issue Date	Aug. 16, 2016
Warrants Outstanding	40,000
Exercise Price \| $ / shares	$ 3.75
Warrants Exercisable	40,000
Expiration Date	Aug. 16, 2021
Lender Warrants One [Member]
Issue Date	Jul. 19, 2017
Warrants Outstanding	615,386
Exercise Price \| $ / shares	$ 2.08
Warrants Exercisable	615,386
Expiration Date	Jul. 19, 2024

Income Taxes (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Deferred tax asset valuation allowance	$ 500	$ 3,700
Federal net operating loss carryforwards	65,874
Federal research and development tax credits	$ 354
Federal research and development tax credits expiration date	2026
State net operating loss carryforwards	$ 67,538
State net operating loss expiration date	2017
State research and development tax credits	$ 305

Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Current: Federal
Current: State	8	6
Total current	8	6
Deferred: Federal	669	3,294
Deferred: State	(148)	440
Deferred: Change in valuation allowance	(521)	(3,734)
Total deferred	0	0
Income tax provision (benefit)

Income Taxes - Schedule of Income Tax Reconciliation (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
U.S. federal statutory tax rate	21.00%	21.00%
Benefit of lower tax brackets	0.00%	0.00%
State tax benefit, net	(6.73%)	0.04%
Research and development credits	(0.00%)	(0.14%)
Employee stock-based compensation	3.10%	0.46%
Loss on debt conversion	0.00%	0.00%
Capitalization of Subsidiary	0.00%	0.00%
Change in Rate	0.00%	0.00%
Other	(358.67%)	0.13%
Valuation allowance	334.57%	(21.93%)
Effective income tax rate	(6.73%)	(0.44%)

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
NOLs	$ 19,827	$ 19,726
Depreciation and amortization	224	30
Other	640	604
Research and development credits	596	617
Deferred stock compensation	3,533	3,036
Basis Difference in Melt	(1,185)
Basis Difference in Surface	(1,119)	(1,464)
Basis Difference in Eton	(7,528)	(6,340)
Capital Losses	62
Park stock purchase identifiable intangibles	(270)	(484)
Limitation Under 163(j)	299
ASC 842 Lease Liability	2,082
ASC 842 ROU Asset	(1,959)
Total deferred tax assets, net	15,202	15,723
Valuation allowance	(15,202)	(15,723)
Net deferred tax liabilities

Income Taxes - Schedule of Change in Unrecognized Tax Benefits (Details)	12 Months Ended
	Dec. 31, 2019 USD ($)
Income Tax Disclosure [Abstract]
UTB, Beginning balance
Additions for tax positions related to current year
Additions/(reductions) for tax positions related to prior years
UTB, Ending balance

Employee Savings Plan (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Retirement Benefits [Abstract]
Percentage of salary deposits in tax deferred investment account	100.00%	100.00%
Percentage of contributions made by the company	4.00%	4.00%
Contributions by the company	$ 312	$ 248

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	1 Months Ended							12 Months Ended		36 Months Ended
	Dec. 31, 2019	Oct. 31, 2019	Jul. 31, 2019	May 31, 2019	Mar. 31, 2018	Jan. 31, 2018	Apr. 30, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019
Business acquisition description								In consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the first investigational new drug application ("IND") with the FDA for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company's development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors.
Accounts payable and accrued expenses	$ 371							$ 371	$ 245	$ 371
Royalty payments					$ 64	$ 44		846	561
Allergan USA, Inc. [Member]
Lost profit damages				$ 49
Settlement Agreement [Member]
Accrued damages									$ 640
Damages low claim rate, percentage									1.40%
Litigation amount paid		$ 571
Sales and Marketing Agreements [Member]
Additional paid in capital and stock based payments								159	$ 42
Commission expense incurred								2,700	1,511
Sales and Marketing Agreements [Member] \| Minimum [Member]
Commission payments, percentage										10.00%
Sales and Marketing Agreements [Member] \| Maximum [Member]
Commission payments, percentage										14.00%
License Agreement [Member] \| Richard L. Lindstrom, M.D [Member] \| Initial Payment [Member]
Royalty payments							$ 50
License Agreement [Member] \| Richard L. Lindstrom, M.D [Member] \| Second Payment [Member]
Royalty payments							50
Net sales							50
License Agreement [Member] \| Richard L. Lindstrom, M.D [Member] \| Final Payment [Member]
Royalty payments							50
Net sales							$ 100
License Agreement [Member] \| Mayfield Pharmaceuticals, Inc. [Member]
Number of shares issued			300,000
License Agreement [Member] \| Stowe Pharmaceuticals, Inc. [Member]
Number of shares issued			1,750,000
Klarity License Agreement [Member] \| Richard L. Lindstrom, M.D [Member]
Royalty payments								103	118
Royalty payment description							Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold.
Milestone payment in cash	$ 63							63	122	$ 63
Milestone payments on payables								28	$ 15
Injectable Asset Purchase Agreement [Member] \| Richard L. Lindstrom, M.D [Member]
Royalty payments								40
Royalty payment description	The Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold.
Milestone payment in cash	$ 0							0		0
Milestone payments on payables								40
Injectable Asset Purchase Agreement [Member] \| Richard L. Lindstrom, M.D [Member] \| Initial Payment [Member]
Royalty payments	$ 33
Presbyopia Asset Purchase Agreement [Member] \| Richard L. Lindstrom, M.D [Member]
Royalty payments								0
Royalty payment description	The Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net sales, dependent upon the final formulation and patent protection of the Presbyopia Product sold.
Milestone payment in cash	$ 0							0		$ 0
Milestone payments on payables								$ 0

Segment Information and Concentrations (Details Narrative) - Segment	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Number of reportable segment	2
Maximum percentage of sales derived from large number of customer	10.00%	10.00%
Three Main Suppliers [Member]
Percentage of drug and chemical purchases from three main suppliers	73.00%	51.00%

Segment Information and Concentrations - Schedule of Segment Net Revenues, Segment Operating Expenses and Segment Contribution (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Total Revenues	$ 51,165	$ 41,372
Cost of sales	(16,749)	(16,521)
Gross profit	34,416	24,851
Selling, general and administrative	33,096	29,243
Research and development	2,083	825
Segment contribution	8,407
Amortization	209
Asset sales and impairments, net	4,040
Operating loss	(4,803)	$ (5,217)
Corporate [Member]
Operating loss	8,245
Research and Development Expense [Member]
Operating loss	716
Pharmaceutical Compounding [Member]
Total Revenues	51,165
Cost of sales	(16,749)
Gross profit	34,416
Selling, general and administrative	24,468
Research and development	1,006
Segment contribution	8,942
Pharmaceutical Drug Development [Member]
Total Revenues
Cost of sales
Gross profit
Selling, general and administrative	174
Research and development	361
Segment contribution	$ (535)